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Abstract 
A Study on Rheological Properties of Blood  
and Improvements with High-Voltage Plasma Discharge 
Jin Mu Jung 
Dr. Young I. Cho 
Blood behaves as a shear-thinning non-Newtonian fluid where its viscosity 
varies due to both the deformability and aggregation of RBCs with the interaction 
with macro-molecules in blood plasma. The elevated whole blood viscosity (WBV), 
which indicates the increased frictional resistance between a moving blood and 
stationary vessel walls, has been suggested as one of the major determinants or risk 
factors of atherosclerosis diseases (i.e., cardiovascular diseases, stroke, and 
peripheral arterial diseases etc.) and microvascular disorders (i.e., diabetic 
retinopathy, nephrophathy, and neuropathy etc.) by causing both the endothelial 
injury of vessel walls and poor perfusion at capillaries.  
In order to investigate the shear-thinning non-Newtonian behavior of blood 
in regards to the effects of increased wall shear stress and impaired oxygen delivery 
on various diseases that might be caused by hyperviscosity, the present study was 
focused on the studies of rheological properties of blood by examining the WBV 
profiles over a pathologically wide range of shear rates using a scanning capillary 
tube viscometer (SCTV) and their improvements using high-voltage plasma 
discharge. 
Firstly, a new hematocrit-correction model using the Casson model was 
proposed to correct the measured WBVs of different blood samples with different 
hematocrits to a standard hematocrit of 45 %, a process which is needed to compare 
xv 
 
the effect of intrinsic rheological properties or other determinants on blood viscosity 
for different blood samples. Without the measurement of plasma viscosity, the new 
model showed about 4 to 6 times more accurate and less deviations than the 
conventional Matrai’s model. 
Secondly, a new method of measuring the electric conductivity of whole 
blood was introduced for the purpose of hematocrit determination, demonstrating a 
simple but accurate hematocrit measurement by employing a low-frequency square-
wave voltage signal in a conductance cell, without the usual error associated with the 
sedimentation of erythrocytes. 
Thirdly, a new physical treatment method with the application of high-
voltage plasma discharges (i.e. DBD and corona discharge) followed by filtration of 
the coagulated particles was proposed. The results indicated that WBV could be 
reduced by 9.1 % and 17.7 % for systolic blood viscosity (SBV) and diastolic blood 
viscosity (DBV), respectively, from the baseline values when DBD-treated blood 
plasma was filtered prior to mixing with red blood cells. When treated with the 
corona discharge for 60 pulses, DBV and LDL concentration dropped by 30.1 % and 
31.5 %, respectively, from the baseline values.  
Lastly, a new opaque standard viscosity fluid (SVF) was proposed using 
maltose with 55 % of concentration to replicate a shear-thinning non-Newtonian 
behavior of blood for different shear rates. The produced viscosity profiles from three 
different levels of SVFs provided low-, medium-, and high-standard viscosity fluids 
that can be used for the performance test of any blood viscometers over a wide range 
of shear rates. The applicability of new opaque SVFs was demonstrated by dye 
concentration test, repeatability test, and degradation test. 
xvi 
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CHAPTER 1: INTRODUCTION 
1.1 Needs to Study Blood Viscosity 
1.1.1 Introduction to Blood Viscosity 
Blood viscosity is the frictional resistance between a moving blood and 
stationary vessel walls, which represents the thickness and stickiness of blood. Since 
about 45% of blood volume is made up of suspended cellular particles, primarily red 
blood cells (RBCs), the blood behaves as a non-Newtonian fluid where its viscosity 
varies with shear rates (i.e., the ratio of flow velocity to lumen diameter). From a 
rheological point of view, when blood moves at a high velocity during systole, blood 
viscosity becomes relatively low (shear thinning), with RBCs maximally deformed 
(ellipsoid) and dispersed to reduce flow resistance. During diastole, blood viscosity 
increases exponentially as RBCs tend to aggregate, a phenomenon which is caused 
by the interactions between RBCs and molecules existing in blood plasma [1, 2].  
Whole blood has a relatively large range of viscosity, 4-45 cP (40-450 mP) 
with the change of shear rates. The systolic blood viscosity (SBV) measured at a 
shear rate of 300 s-1 has a normal value of about 3.8 cP (38 mP). The diastolic blood 
viscosity (DBV) measured at a shear rate of 1 s-1 has a normal value of about 20 cP 
(200 mP), which is about five times greater than the SBV due to the aggregation of 
RBCs [3]. 
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1.1.2 Significance of Blood Viscosity Related to Cardiovascular Disease 
 According to the World Health Organization (WHO), cardiovascular 
diseases were the number one cause of death among the top ten causes of death 
globally. WHO also reported that, in 2008, an estimated 17.3 million people died 
from cardiovascular diseases, representing 30% of all global deaths. It was estimated 
that, by 2030, almost 23.6 million people would die from cardiovascular diseases, 
mainly from heart disease and stroke (cited from WHO website: www.who.int). 
 In the United States, mortality data reported by the American Heart 
Association (AHA) in 2011 showed that 0.8 million deaths of all 2.4 million deaths 
in 2007 were caused by cardiovascular disease, i.e., one in every three deaths, see 
Fig. 1-1. It also reported that, on the average, more than 2,000 Americans die of 
cardiovascular diseases each day, an average of 1 death every 40 seconds [4]. Of 
deaths due to cardiovascular disease, coronary heart disease and stroke accounted for 
more than 65 % because of their acute symptoms, see Fig. 1-2. 
 
19 
 
 
Figure 1-1. Deaths due to cardiovascular disease in the United States between 1900-
2007 (source: National Center for Health Statistics & AHA) [4] 
 
  
 
Figure 1-2. Percentage breakdown of deaths due to cardiovascular disease in the 
United States in 2007 (source: National Heart, Lung, and Blood Institute from 
National Center for Health Statistics reports and AHA) [4] 
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 Figure 1-3 also shows that deaths by cardiovascular disease claims more 
lives each year than those by cancer. Referred from the report by Xu et. al. and AHA, 
in every year since 1900 except for 1918, cardiovascular diseases accounted for more 
deaths than any other major causes of death in the United States [4, 5].  
 
 
 
Figure 1-3. Cardiovascular disease deaths versus cancer deaths by age of the United 
States in 2007 (source: National Center for Health Statistics & AHA & Xu et al) [4, 5] 
 
 
 The risk factors for cardiovascular diseases such as coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, thrombosis, and pulmonary 
embolism have been investigated and known to be affected by a number of factors 
such as fibrinogen, glucose, total cholesterol, LDL cholesterol, triglyceride, blood 
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pressure, smoking, diabetes etc.[1-4, 6-18]. 
However, most of researches in the field of cardiovascular disease, 
especially atherosclerosis and microvascular disorder, which are typically considered 
as two pathophysiological but contrasting manifestations related to blood flow, have 
been focused on the histology of blood and vessel wall chemistry [2]. It has been 
generally recognized that atherosclerosis is an ongoing sterile inflammatory process 
that begins with functional impairment of the arterial endothelium, whereas 
microvascular disorder is related to poor perfusion at small micro-vessels, leading to 
capillary loss [3]. However, the causes of both the endothelial injury of vessel walls 
and poor perfusion at capillaries have been remained incomplete from a biochemical 
perspective. Recently, it has become possible to explain the causes by shifting the 
perspective of understanding from a biochemical approach to a biomechanical one [2, 
3]. 
The key concepts of the biomechanical approach to those diseases related to 
blood circulation are as follows:  
1) The circulatory vascular system can be considered as a closed 
mechanical piping system in which the energy pumped by the heart must 
be absorbed by the arterial system [2]. 
2) A vascular element can be considered as a dynamically responsive organ 
producing autocrine and paracrine factors that may be regulated 
functionally by local hemodynamic shear stress [19-25]. 
3) The microvascular shear stress needs to exceed the yield stress (or 
22 
 
attractive forces between cells and macro-molecules) of blood in order to 
maintain capillary flow. If not, ischemia and capillary loss may be 
triggered [3]. 
 
Stating from those biomechanical concepts, the initial injury and subsequent 
events resulting in atherosclerosis could be explained as follows:  
The resistance of vasculatures rises with the increase of WBV and thus, 
systolic pressure must increase to ensure the same circulating blood volume, in other 
words, for a constant cardiac output to be maintained [2, 26]. In the first phase 
(according to the protective adaptation theory), compliant arteries respond 
protectively at the cellular level to overstretching caused by an elevated blood 
pressure. This over-stretching results in arterial wall thickening, hardening, and 
subsequent loss of compliance (or called arteriosclerosis). After arteriosclerosis (i.e., 
the loss of arterial compliance) has developed [2], as blood passes through a 
bifurcation with a more injurious force, blood decelerates along the outer wall of the 
bifurcation, greatly reducing the local shear rate at the outer wall [23]. This causes 
WBV at the outer wall of the bifurcation (i.e., a low-shear-rate area) to be much 
oscillatory than that at the wall of the main lumen (i.e., a high-shear-rate area). This 
phenomenon causes endothelial dysfunction, which triggers subsequent vascular 
remodeling by the activation of endothelium, inflammation, the alteration of lipid 
metabolism, and finally the progression of atherosclerotic vascular diseases [3, 23]. 
Thus, atherosclerosis is a geometrically focal [23, 27], site-specific disease which 
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includes the carotid artery bifurcation, as well as the coronary, infrarenal, and 
femoral artery vasculatures. On the contrary, the arteries of the arms and breasts, and 
the veins are free of plaques formation [2]. 
Adopting the biomechanical concepts mentioned above, the capillary loss, a 
common outcome of microvascular diseases due to the stasis of blood flow, can also 
be explained as follows:  
The yield stress can be defined as the minimum shear stress required to 
maintain a continuous flow of blood [28]. The physical origin of the yield stress is 
the attractive forces (i.e., ion bridges, hydrogen bonds, electrostatic charges, van der 
Waals forces etc.) between RBCs and the macro-molecules suspended in blood 
plasma medium. Thus, when the yield stress is greater than the shear forces exerted 
by the flow itself, hemostasis could occur locally due to the rapid interlocking of 
cells [3, 16, 29]. Subsequently, capillary loss could occur due to stoppage of oxygen 
delivery. Unless the shear stress of blood exceeds the yield stress, the perfusion at 
capillaries may not be maintained, then ischemia and capillary loss could be 
triggered [3].  
The researches concerning the link between the elevated whole blood 
viscosity (WBV) and related diseases have been increased steadily. Both 
experimental and clinical data clearly have shown that the flow behavior of blood is 
a major determinant or risk factor of atherosclerosis diseases (i.e., cardiovascular 
diseases, stroke, and peripheral arterial diseases etc.) and microvascular disorder (i.e., 
diabetic retinopathy, nephrophathy, and neuropathy etc.) [1-3]. 
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For specific examples, a positive relation between blood viscosity (or 
components of blood viscosity) and renovascular/essential hypertension has been 
reported [9, 30-32]. Blood viscosity has also been implicated as a determinant of 
hypertensive cardiac hypertrophy and peripheral vascular disease [9, 26, 33]. 
Moreover, elevated WBV may be a determinant of coronary artery disease, either 
indirectly because of its relation with systemic hypertension or directly because of its 
amplification of the resistance, with adverse effects on both clinical manifestations 
of coronary disease and myocardial oxygen delivery [2, 9, 26, 30-36]. 
Thus, abnormal (or increased) WBV makes a significant contribution to the 
pathophysiology of major sources of morbidity and mortality, such as cardiovascular 
and microvascular disorder, which could be risk factors or biomarkers for prediction, 
diagnosis, and treatment of those disorders [1-3, 37]. 
 
1.2. Methods to Measure Blood Viscosity 
1.2.1 Conventional Methods to Measure Blood Viscosity 
As the importance of WBV has been continuously increased, various 
experimental methods have been developed, where in vitro models of in vivo flow 
situation have been constructed using rotational or capillary viscometers, and 
relevant information on blood viscosity has been experimentally and clinically 
investigated [38].  
The viscosity of blood has been measured using several types of 
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viscometers such as a rotational-type viscometer and a capillary-type viscometer [39]. 
However, those conventional viscometers have allowed the measurement of viscosity 
at a single point of shear rate [1, 2]. The value of blood viscosity measured at a 
single shear rate cannot fully describe the behavior of a non-Newtonian fluid, which 
represents dynamic properties of blood by complicated interactions between the 
suspended cell and molecules in blood [3]. Thus, it is required to measure blood 
viscosity over a wide range of physiologically relevant shear rates (i.e. from 1 s-1 to 
1,000 s-1) in order to understand the behavior of blood as a non-Newtonian fluid, see 
Fig. 1-4.  
 
 
Figure 1-4. Curves of WBV versus shear rates from 1 to 1,000 s-1 for normal and 
hardened RBCs in blood plasma [1, 2] 
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When a rotating viscometer is alternately used to measure blood viscosity at 
multiple points of share rates, it is not only a time-consuming but also could 
influence the validity of viscosity measurement as the blood cells could be ruptured 
by several sudden changes of shear rates for a relatively long-time measurement. In 
addition, the structural limitation of a rotating (i.e., spring sensitivity) viscometer 
provides inaccurate results at physiological shear rates less than 1 s-1. A capillary 
viscometer was often used to measure plasma viscosity at a single maximum shear 
rate. Thus, it is not proper to conduct the measurement of whole blood viscosity for 
multiple shear rates with the capillary viscometer. Furthermore, these two techniques 
require the direct handling of blood and manual cleaning of the equipment, the 
processes which could cause a potential risk for the operator to make contact with 
contaminated blood [2].  
Those limitations of conventional viscometers in laboratory measurements 
have led the researchers to measure whole blood viscosities at several specific points 
of shear rates (i.e., shear rates of 1, 5, 208 s-1, etc.) instead of a wide range of shear 
rates [9], limiting clinical applications of blood viscosities.  
 
1.2.1 Scanning Capillary Tube Viscometer (SCTV) 
In order to understand the overall characteristics of flow behavior of blood, 
one needs to measure the viscosity of blood for a pathologically wide range of shear 
rates (i.e., from 1 to 1,000 s-1), which could be related to a critical risk factor or 
biomarker for diagnosis and treatment of cardiovascular and microvascular diseases 
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[1-3]. Depending on these necessities, an automated scanning capillary tube 
viscometer (SCTV) using a U-shaped disposal tube (Hemathix in USA / BVD in 
South Korea) has been developed, which can measure the viscosity of whole blood 
over a wide range of shear rates (i.e., from 1 to 1,000 s-1) by one-time measurement 
[40-44].  
 
 
 
Figure 1-5. Schematic diagram of the SCTV system for blood viscosity measurement 
used in the present study [41, 43] 
 
 
28 
 
As seen in Fig. 1-5, two charge-coupled devices (CCDs) and two light-
emitting diodes (LEDs) are vertically installed in the SCTV system to detect height 
changes of blood along two riser tubes. This system is using a Casson model to 
mathematically describe the non-Newtonian behavior of blood viscosity using a yield 
stress term as follows:  
√τ = ඥτ୷ + √kඥγሶ 						when			τ ≥ τ୷            (Eq. 1-1) 
γሶ = 0				when		τ ≤ τ୷ 
where τ	 denotes the shear stress by the flow of blood, γሶ  is the shear rate, τ୷ is the 
yield stress, and k is a Casson model constant.  
The mean flow velocity at the riser tube can be obtained as a result of 
calculating the flow rate at the capillary tube using the expressions of shear rate and 
pressure drop across the capillary tube from the Casson model. Then, the unknowns, 
such as a Casson constant, height difference, and additional effect on height 
difference by surface tension, can be determined through curve-fitting procedure 
using the height measurements, and the derivative of the height difference at the riser 
tube [41, 44]. Thus, the apparent viscosity, η, can be calculated as follows [44]: 
η	(t) = k +	
(ಙౝ౎౛∆౞౯మైౙ )
ஓ	ሶ (୲) +
ටమౡಙౝ౎౛∆౞౯ైౙ
ඥஓ	ሶ (୲)            (Eq. 1-2) 
where,   ρ = the density of blood 
g = gravitational acceleration 
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Rୣ = Reynolds number 
∆h୷ = the height of blood at riser tube 
Lୡ = the length of capillary tube    
Once the measurement is initiated in the SCTV, the Riser tube 1 is filled with 
blood up to a pre-determined height. Then, as a three-way valve rotates, the blood in 
the Riser tube 1 moves to Riser tube 2 through a glass capillary tube. Here, the SCTV 
system continuously measures the height difference of fluids moving in the two 
vertical riser tubes, which replicates high shear flow when the height difference is 
large, and low shear flow when the height difference gradually reduces. Detailed 
mathematical descriptions are given elsewhere [41, 44].  
 
1.3 Objectives of the Present Study 
As the WBV profile over a pathologically wide range of shear rates can be 
measured using the SCTV, clinical experiments can be conducted in order to 
investigate the effect of blood viscosity on various diseases that might be caused by 
hyperviscosity of blood, in regards to the effects of increased shear stress or yield 
stress and impaired oxygen delivery on the diseases related to blood circulation (i.e. 
cardiovascular diseases, diabetes, retinal vein occlusion, hemodialysis etc.). 
Accordingly, it has also become important on how to utilize the measured 
blood viscosity information in order to derive meaningful interpretation with 
experimental and clinical significance.  
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Thus, the present study was focused on the studies of hemorheological 
properties of blood related to blood viscosity over a wide range of shear rates. For 
example, the present study examined a new method to correct the WBV profiles for 
reliable analysis, the incorporation of the WBV results with other hemorheological 
properties (i.e. hematocrit) to indicate oxygen delivery index, the improvement (or 
reduction) of blood viscosity by applying electrical plasma discharges, and the 
proposal of a standard viscosity fluid for blood viscosity measurements using the 
SCTV.  
The detailed objectives of the present study are as follows: 
Objective 1 was to investigate a new procedure for the correction of the measured 
blood viscosity over a wide range of shear rates (i.e., from 1 to 1,000 s-1) to a 
standard hematocrit of 45 % using a constitutive equation describing a non-
Newtonian behavior of blood, the Casson model. 
Objective 2 was to conduct a research and development on an on-line hematocrit 
conductance cell in order to automatically determine the oxygen delivery index.  
Objective 3 was to investigate the feasibility of the improvement of WBV (or 
reduction of WBV) by applying high-voltage plasma discharge to blood. The 
mechanism of the change of blood viscosity by the electric plasma discharge was 
also studied over a wide shear rate range.  
Objective 4 was to conduct a research and development on a new standard viscosity 
fluid for blood viscosity measurements. 
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CHAPTER 2: A NEW HEMATOCRIT-CORRECTION MODEL 
2.1 Motivations and Literature Survey on the Correction of WBV 
Hematocrit, the volume fraction of red blood cells in whole blood, is the 
main determinants of blood viscosity. Depending on the deformability of red blood 
cells, blood viscosity can increase by approximately 20 % with increase of hematocrit 
by 10% [2]. Since hematocrit and blood viscosity has an exponential relation, blood 
viscosity becomes increasingly dominant to hematocrit alterations at higher levels of 
hematocrit. It is also known that there is about 4% increase of blood viscosity per unit 
increase of hematocrit at medium to high shear rates [1, 15]. 
Thus, in order to evaluate the effect of intrinsic rheological properties or 
other determinant on blood viscosity, it requires estimating the rheological properties 
of different blood samples with different hematocrits at the same hematocrit value (i.e. 
45 % hematocrit). This can be achieved by reconstituting blood samples of different 
hematocrits to a standard hematocrit (i.e. 45 %) [45] by adding blood plasma to 
samples with hematocrit over 45 % or removing blood plasma from samples with 
hematocrit below 45%. However, this procedure could not only cause artifacts during 
reconstituting hematocrit values, but also be impractical in clinical applications where 
the likelihood of infection always exists.  
Alternatively, Matrai et al. [45] introduced a hematocrit-correction model by 
adopting plasma viscosity to the correction of the measured WBV to a standard 
hematocrit of 45 %. The method proposed by Matrai et al. has been widely used for 
correction at different hematocrits [46]. On this basis, the measured WBV at native 
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hematocrit could be mathematically corrected to the WBV at a standard hematocrit of 
45 % as follows [45]: 
ஜ	రఱ%	౞ౙ౪
ஜౌ౒ = ቂ
ஜ	౤౗౪౟౬౛	౞ౙ౪
ஜౌ౒ ቃ
రఱ
ౄౙ౪                   (Eq. 2-1) 
Where μସହ%	୦ୡ୲ is the corrected WBV to a standard hematocrit of 45 %, μ୬ୟ୲୧୴ୣ	୦ୡ୲ is 
the measured WBV at native hematocrit, μ୔୚ is plasma viscosity (blood viscosity at 
0 % hematocrit), and Hct is the measured native hematocrit [%], respectively [45]. 
Due to its simplicity in calculating the corrected blood viscosity, Matrai’s 
model has been widely utilized, considering the effects of unequal hematocrit and 
thus allowing the direct comparison of WBV values at the same hematocrit of 45 % 
[47].  
Lowe et al. [33] performed a study on the association of blood rheological 
factors, such as WBV, plasma viscosity, hematocrit, fibrinogen, and activation of 
coagulation in patients with lower limb ischemia. Blood samples were measured in 
random samples of 1,581 men and women aged 55 to 74 years in Edinburgh, 
Scotland and the measured WBVs were corrected to a standard hematocrit of 45 % 
using the Matrai’s model. As a results of multivariate analysis, it was found that 
blood viscosity (p < 0.05) and fibrinogen (p < 0.01) were independently associated 
with peripheral arterial narrowing associated with lower limb ischemia in the general 
population which may be implicated in its pathogenesis [33].  
Using another results from the same Edinburgh Artery Study, Amanda et al. 
[48] also studied the relationship between rheological factors and carotid intima-
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media thickness (IMT). During 1988-1989, for baseline, the Edinburgh Artery Study 
measured whole blood and plasma viscosities, and hematocrit including other critical 
factors (i.e. fibrinogen, tissue plasminogen activator (tPA), fibrin D-dimer, von 
Willebrand factor (vWF)) from 1,106 men and women 60 to 80 years old. Then, 5 
years of follow-up measurements of IMT had been performed, where the measured 
WBVs were corrected to a standard hematocrit using the measured plasma viscosity 
and native hematocrit. The results showed that, in men, blood viscosity and its major 
determinants were linearly related to IMT, suggesting that blood viscosity was 
associated not only with incident cardiovascular events but also with the early stages 
of atherosclerosis [48]. 
Freyburger et al. [49] investigated the effects of five different plasma 
substitutes, which were commonly used in preoperative normovolaemic acute 
haemodilution, on rheological properties such as WBV and plasma viscosity. WBV 
and plasma viscosity were measured using Contraves LS 30 rotational viscometer at 
low shear rate, 1 s-1, and high shear rate, 128.5 s-1. The measured WBVs were 
mathematically corrected using Matrai’s model resulting in that the five substitutes 
had very different effects on red blood cell aggregation and the corrected WBV at low 
shear rate (mostly dominant by red blood cell aggregation) was reduced in the 
presence of 4% human albumin (HA) and 3.5% dextran 40 (Dxt 40), but was 
increased moderately in the presence of 6% dextran 60 (Dxt 60), 6% 
hydroxyethylstarch 200 (HES), and modified fluid gelatin (Gel) in the following 
order: HES < Dxt 60 < Gel. 
Lee et al. [47] evaluated the pathophysiological abnormalities of stable 
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angina (SA) and acute coronary syndromes (ACS) promoted by the rheological 
properties of blood. WBV and plasma viscosity of blood samples collected from 16 
healthy, 16 SA, 18 unstable angina (UA), and 19 acute myocardial infarction (AMI) 
patients were measured and corrected to a standard hematocrit (i.e. 40 %) as shown in 
Fig. 2-1. The yield stress was calculated using the Casson Equation in order to 
estimate fluid forces associated with local blood flow. The study showed an 
association between hemorheological abnormalities and the severity of coronary 
artery disease [47]. 
 
 
Figure 2-1. Differences in blood viscosity between native hematocrit (left) and 
corrected hematocrit (right) cases for control, stable angina, unstable angina and 
acute myocardial infarction patients [47] 
 
At the same manner, Lee et al. also investigated the association of 
microcirculatory dysfunction in cardiac syndrome X (CSX) with abnormalities of 
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blood rheology (i.e. blood viscosity and red blood cell aggregation), showing that  
CSX patients had markedly abnormal blood rheology such as elevated hematocrit-
corrected blood viscosity, plasma viscosity and yield stress including higher red blood 
cell aggregation [50]. 
Box et al. [46] investigated the effects of blood viscosity, variations in flow 
rate,  and vessel diameter on plaque development which particularly occurs in the 
recirculation region at a carotid bifurcation where local wall shear stress oscillates. In 
accordance with the results given by Matrai’s model where WBV is exponentially 
dependent on the increased hematocrit levels, Box et al. proposed to replace the 
power-law index n in the Carreau-Yasuda (CY) model by hematocrit and performed a 
numerical simulation by means of the finite element method. As shown in Fig. 2-2, 
maximum WSS oscillation was found at the edges of the recirculation region at a 
carotid bifurcation and proposed a possible adoption of the CY model to incorporate 
the differences of blood viscosity caused by the difference in hematocrits.  
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also additional process to separate cells from blood plasma to measure plasma 
viscosity using either a capillary tube viscometer (i.e. Ostwald viscometer) or a cone-
and-plate rotating viscometer (i.e. Brookfield viscometer) [17, 39]. The non-
disposable structures of both the capillary tube viscometer and the rotating 
viscometer need manual cleaning after each measurement, a process which could 
cause time-consuming and a potential risk for the operator to contact with 
contaminated blood. 
Thus, it is necessary to propose a new hematocrit-correction model that does 
not require additional measurements of plasma viscosity, but with a WBV alone.  
In addition, while Matrai’s model was developed based on blood viscosity 
measured with LS-30 viscometer at two specific shear rates of 0.7 and 94.5 s-1 [45], 
the scanning capillary tube viscometer (SCTV) utilized in the present study was able 
to produce WBV profile over a wide range of shear rates [41, 43, 44]. Thus, it would 
be also interesting to investigate the validity of the Matrai’s model on the correction 
of WBV over a wide range of shear rates. 
Thus, the objectives of the present chapter was to propose a new procedure 
to correct blood viscosity to a standard hematocrit (i.e. 45 % hematocrit) without 
actual measurement of plasma viscosity and investigate the validity of the Matrai’s 
model over a wide range of shear rates (i.e. from 1 to 1,000 s-1).  
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2.2 Methods 
2.2.1 Sample Preparation 
Blood samples were obtained from three healthy volunteers into each 200 
mL-evacuated glass bottle which contained 2.0 mL of ethylene diaminetetra-acetic 
acid (EDTA) as an anti-coagulant. Hematocrits of the three blood samples were first 
measured using a microcenrifuge (StatSpin MP, Iris) to determine the amount of 
blood plasma required to reconstruct the whole blood samples for 25, 30, 35, 40, 45, 
50, 55, and 60 % hematocrit values. 
The whole blood in the 200 mL-glass container was then transferred to 10 
mL-polyethylene tubes to separate cells using a centrifuge (Fleta 5, Hanil ) at 1,500 G 
of relative centrifugal force (RCF) for 15 min. After the completion of centrifuge, 
hematocrit values were carefully adjusted into 25, 30, 35, 40, 45, 50, 55, and 60 % 
(which were considered to be clinically possible ranges of hematocrits) by adding or 
removing blood plasma according to the following equation to calculate the required 
volume of blood plasma for reconstructing blood samples to target-hematocrit values: 
Required volume of plasma (mL) = 
(ଵ଴଴ି୲ୟ୰୥ୣ୲	ୌୡ୲)	୶	(ୡ୳୰୰ୣ୬୲	ୌୡ୲)
ଵ଴	୶	(୲ୟ୰୥ୣ୲	ୌୡ୲	)      (Eq. 2-2) 
Since transferring red blood cells directly from the centrifuged 10-mL 
container to another one could possibly cause hemolysis, which is the destruction of 
thin and weak membrane surface of red blood cells, blood plasma was added into or 
removed from the centrifuged 10-mL containers instead of transferring red blood 
cells.  
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For example, when hematocrit of blood sample was 48 %, one could 
calculate additional volume of blood plasma required to prepare a 30 %-hematocrit 
adjusted sample as follows: 
Required volume of blood plasma (mL) = 
(ଵ଴଴ି୲ୟ୰୥ୣ୲	ୌୡ୲)	୶	(ୡ୳୰୰ୣ୬୲	ୌୡ୲)
ଵ଴	୶	(୲ୟ୰୥ୣ୲	ୌୡ୲	)     
= (ଵ଴଴ିଷ଴)	୶	(ସ଼)ଵ଴	୶	(ଷ଴)  = 11.2 mL   (Eq. 2-3) 
Thus, the hematocrit values could be reconstituted by adding 6 mL of 
additional blood plasma to the original blood sample with 48 % hematocrit. The 
required volume of blood plasma calculated to adjust for different hematocrit values 
are given in Table 2-1. 
 
Table 2-1. Examples of the required volume of blood plasma to reconstitute to target-
hematocrit values 
 
Con
trol Target-hematocrit values to adjust 
48 % 25 % 30 % 35 % 40 % 45 % 50 % 55 % 60 % 
Red 
blood 
cell  
(mL) 
4.8 
mL 
4.8  
mL 
4.8 
mL 
4.8 
mL 
4.8 
mL 
4.8 
 mL 
4.8 
mL 
4.8  
mL 
4.8  
mL 
Total 
volume 
of blood 
plasma 
(mL) 
5.2 
mL 
14.4 
mL 
11.2 
mL 
8.9 
mL 
7.2 
mL 
5.9 
mL 
4.8 
mL 
3.9 
 mL 
3.2  
mL 
Required 
blood 
plasma 
(mL) 
- 
Add 
9.2 mL 
Add 
6 mL 
Add 
2.7 mL
Add 
2 mL 
Add 
0.7 mL
Remove
0.4 mL
Remove 
1.3.mL 
Remove 
2 mL 
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2.2.1 Measurement of WBV and Plasma Viscosity  
After the procedure to reconstruct hematocrit values was completed, all the 
hematocrit-adjusted blood samples were gently mixed using a roller-type mixer in 
order to have the centrifuged red blood cells uniformly dispersed and mixed evenly 
with blood plasma. Then, hematocrit values for all the hematocrit-adjusted blood 
samples were measured again to verify that they were correctly adjusted to the target 
hematocrit values. 
The hematocrit-adjusted blood samples in 10 mL-polyethylene tubes were 
then divided into two 4-mL plain vacutainers for WBV measurement. WBV was 
measured at 37oC using the SCTV over a range of shear rates from 1 to 1,000 s-1. 
Detailed test and viscosity calculation procedures are given elsewhere [43, 44] 
In order to measure plasma viscosity, two 10-mL of whole blood samples 
were taken from a 200-mL evacuated glass bottle and transferred to two 10-mL- 
polyethylene tubes for centrifuge. After cells in whole blood were separated from 
blood plasma, blood plasma in the tubes was moved into two 4-mL-plain vacutainers. 
Dye of about 0.2 % concentration by weight was added to make blood plasma opaque 
and then the viscosity of blood plasma was also measured using the SCTV. 
The effect of adding dye on the change of viscosity had been investigated 
elsewhere and confirmed that it did not alter the magnitude of fluid viscosity as long 
as the dye concentration was less than 2 % concentration in volume [43]. 
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2.2.3 Data Analysis 
Three different whole blood samples obtained from three healthy volunteers, 
respectively, were adjusted to 25, 30, 35, 40, 45, 50, 55, and 60 % hematocrit values. 
In order to increase the accuracy, two samples of a given hematocrit were measured 
per each case, and the viscosity results were averaged.  
The WBV profile generated after WBV measurement contained continuous 
10,000 data points over a range of shear rates from 1 to 1,000 s-1, as shown in Fig. 2-4. 
Due to its difficulties in handling and analyzing all the 10,000 data, several specific 
points of shear rates (i.e. 1, 2, 4, 5, 6, 10, 20, 40, 50, 60, 80, 100, 150, 200, 250, and 
300 s-1) were selected and utilized in both investigating the validity of Matrai’s model 
to the measured WBV profile and proposing a new hematocrit-correction model. 
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Figure 2-4. A WBV profile obtained from WBV measurement using SCTV [41, 44]  
 
Statistical analysis was performed using a linear regression analysis to 
evaluate the correlations between the cube root of the measured yield stress, (or the 
cube root of the Casson constant and hematocrit values. A p-value less than 0.05 was 
considered to be statistically significant, which was the same as having a 95% 
confidence interval.  
The sum of the error for both the correct WBV using a new model and the 
one using the Matrai’s model was calculated to compare the validity of a new 
hematocrit-correction model with the Matrai’s model. 
44 
 
 
2.3 Results and Discussion 
2.3.1. A New Procedure to Correct the Measured WBV  
Human blood is known to have a yield stress, which can be defined as the 
minimum shear stress required to maintain a continuous blood flow [28, 29] or the 
limit of the shear stress when the shear rate approaches zero [3]. Such a yield stress is 
caused by the aggregation of red blood cells at a very low shear rate, and as shear 
stress overcomes the yield stress, red blood cells disperse and blood starts to flow. In 
order to describe such a flow model of particles, the Casson model was utilized in the 
present study. The yield stress can be expressed as shown in (eq. 1-1) [28, 29, 53]. 
By rearranging (eq. 1-1) regarding to a viscosity term, the following 
equation can be obtained: 
η(t) = 	k +	 த౯ஓሶ ౭(୲) 	+ 	
ඥସ୩த౯
ඥஓሶ౭(୲)
              (Eq. 2-4) 
Thus, one can obtain blood viscosity by determining the yield stress, τ୷, and the 
Casson constant, k.  
Interestingly, the yield stress and the Casson constant terms are known to be 
affected by both the particle concentration (i.e. hematocrit) and the viscosity of 
medium (i.e. plasma viscosity) [28, 29]. From this observation, the present study 
offers a hypothesis that, by adopting both the yield stress and the Casson constant 
terms in a new hematocrit-correction model, not only the effect of hematocrit but also 
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the effect of plasma viscosity could be included in the new model. Thus, one might be 
able to substitute a direct measurement of plasma viscosity required in the Matrai’s 
correction model. 
Several methods have been suggested to determine the yield stress and the 
Casson constant based on experimental measurements. Merrill et al. suggested that 
both the yield stress and the Casson constant could be determined by the 
extrapolation of the measured data to the square root of stress axis on the Casson plot, 
the square root of the shear stress versus the square root of the shear rate, within 10% 
of deviation [28, 29]. 
The SCTV utilized in the present study also used the Casson model to 
determine blood viscosity by numerically calculating the yield stress and the Casson 
constant terms over a wide shear rate range. Since the detailed principles of 
measurement of the SCTV were outlined elsewhere [41, 43], a brief description of the 
measurement procedure is given below: 
Step 1.  
The unknowns, such as the yield stress, the Casson constant, height 
difference including the surface tension, can be determined using the 
velocity profile measured at the disposable U- tube with two charge-coupled 
devices (CCDs) and light-emitting diodes (LEDs). 
Step 2.  
The unknowns are determined by the curve-fitting method from the 
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experimental data as the sum of the error is minimized. 
Step 3.  
Then, wall shear rate and viscosity for all data points can be calculated. Thus, 
by measurement using the SCTV, one can obtain both the yield stress,	τ୷, 
and the Casson constant, k. 
 
According to the hypothesis mentioned above, the correlation between 
hematocrit and the yield stress (or the Casson constant) obtained during the WBV 
measurement using the SCTV was investigated.  
The yield stress has been generally known that the cube root of the yield 
stress has a linear relation with hematocrit. Merill et al. [29] showed this correlation 
with the following equation: 
ඥτ୷య = A(H − Hc)                       (Eq. 2-5) 
Where constant A is 0.008, H is hematocrit, and Hc is a critical hematocrit 
when no yield stress exists. Similarly, Zydney et al. [54] also provided a constitutive 
equation of blood viscosity containing the effect of hematocrit, shear rate, and 
suspending phase: 
τ୷ = A(H − 0.05)ଷ                     (Eq. 2-6) 
Where constant A is 0.71 [3]. 
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By adopting those concepts suggested from these previous studies, the cube 
root of the yield stress and the Casson constant obtained from the SCTV 
measurement were plotted in Figs. 2-5 to 2-7 as a function of hematocrit. The y-axis 
was plotted with both the cube root of the yield stress and the Casson constant 
without the consideration of their units, the cube root of millipascal and the cube root 
of centipoise, respectively.  
Prior to further discussion, one needs to set the following assumption in 
order to simplify the current hematocrit-correction model:  
The Casson constant, k, was assumed to be affected by both hematocrit and plasma 
viscosity as was the yield stress, even though the effects of hematocrit and plasma 
viscosity on the Casson constant were lower than those on the yield stress. Based on 
this assumption, the cube root of the Casson constant versus hematocrit was 
considered to be linear as the yield stress. 
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Figure 2-5. The cube root of the yield stress, ૌܡ, and the cube root of Casson constant, 
k, plotted on the same y-axis as a function of hematocrit (Sample A) 
 
 
Figure 2-6. The cube root of the yield stress, ૌܡ, and the cube root of Casson constant, 
k, plotted on the same y-axis as a function of hematocrit (Sample B) 
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Figure 2-7. The cube root of the yield stress, ૌܡ, and the cube root of Casson constant, 
k, plotted on the same y-axis as a function of hematocrit (Sample C) 
 
 
As seen from Figs. 2-5 to 2-7, two separate linear lines could be produced as 
a result of linear regression analysis (P < 0.001) for three different samples. More 
importantly, the two lines crossed each other at a certain identical point for all the 
three samples. 
Combining the three figures into one plot as in Fig. 2-8, it could be clearly 
observed that the two different kinds of linear regression lines, the root cube of the 
yield stress versus hematocrit and the root cube of the Casson constant versus 
hematocrit showed almost identical intersections.  
Even though the point of intersection among the three samples were not 
exactly identical, they crossed very close with little difference, for example, within 
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hematocrit range approximately from 28.4 to 28.9 %, and y-axis approximately from 
1.40 to 1.42.  
 
 
 
Figure 2-8. The combined plot of the cube root of the yield stress, ૌܡ, versus 
hematocrit and the cube root of Casson constant, k, versus hematocrit for Sample A, 
B, and C 
 
 
The difference in the slopes among the three curves in Fig. 2-8 could be 
caused by different plasma viscosities, that is, by different concentrations of plasma 
viscosity determinants (i.e. fibrinogen, LDL etc.) [33, 55]. Even though the difference 
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of y-values measured at higher hematocrit values, as the hematocrit decreased, the 
difference of y-values between the curves became smaller.  
The extrapolation of the Casson constants from three different linear 
regression lines was found to intercept to the y-axis with the values around from 1.0 
to 1.2. Furthermore, the yield stresses from the three different linear regression lines 
were found to extrapolate to the x-axis (indicating a zero yield stress) before the 
hematocrit value on the x-axis reached zero [14, 28, 29], which was termed as a 
critical hematocrit [29]. In the present study, the critical hematocrit obtained by the 
extrapolation of the linear regression lines was from approximately 0.3 to 1.7, which 
was similar to the values by Merill et al. (i.e. from 1.3 to 6.5) [29]. 
Based on these findings, A new hematocrit-correction model was proposed 
with the following procedures: 
Step 1. 
One assumed that the constant value of the intersection between the cube 
root of the yield stress versus hematocrit line and the cube root of the Casson 
constant versus hematocrit line was already experimentally known as 
Constant C1(a, b) on the Casson plot, as shown in Fig. 2-9. 
Step 2. 
The WBV and hematocrit of a blood sample were measured using SCTV and 
a micro-centrifuge, respectively. During the WBV measurement, the yield 
stress, τ୷, and the Casson constant, k	, could be automatically obtained from 
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SCTV. 
Step 3. 
The measured yield stress, τ୷, and Casson constant, k	, during the WBV 
measurement were plotted on the Casson plot with the cube root values, as 
seen in Fig. 2-9, where A1 denotes the cube root of the yield stress, ඥτ୷య , and 
B1 the cube root of the Casson constant, ඥk	య , at native hematocrit, 
respectively. 
 
 
  
Figure 2-9. Casson plot with Constants C1, A1 and B1 
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Step 4.  
According to the linearity relations discussed in the previous section, the 
points between Constant, C1, and the cube root of the obtained yield stress, 
A1, at native hematocrit could be connected with a linear line. In the similar 
way, the points between Constant, C1, and the cube root of the obtained 
Casson constant, B1, at native hematocrit also could be connected with a 
linear line, as shown in Fig. 2-10. 
 
 
Figure 2-10. Casson plot with two linear lines connecting between Constants C1 and 
A1, Constants C1 and B1, respectively 
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Step 5. 
In Fig. 2-11, since the Cartesian coordinates of C1, A1, and B1 on the Casson 
plot were now known, one could determine the location of points A2 and B2 
by simple proportional equations, where A2 is the cube root of the corrected 
yield stress to a standard hematocrit of 45 % and B2 is the cube root of the 
corrected Casson constant to a standard hematocrit of 45 %.  
A2, the calculated cube root of yield stress, ඥτ୷య , at 45 % hematocrit:  
 
୬ୟ୲୧୴ୣ	୦ୡ୲ିୟ
ସହିୟ 	=
୅భିୠ
୅మିୠ                    (Eq. 2-7) 
 
Aଶ = 	 ቂቀ ସହିୟ୬ୟ୲୧୴ୣ	୦ୡ୲ିୟቁ X(Aଵ − b)	ቃ + b        (Eq. 2-8) 
 
B2, the calculated cube root of yield stress, ඥτ୷య , at 45 % hematocrit :  
 
୬ୟ୲୧୴ୣ	୦ୡ୲ିୟ
ସହିୟ 	=
୆భିୠ
୆మିୠ                   (Eq. 2-9) 
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Bଶ = 	 ቂቀ ସହିୟ୬ୟ୲୧୴ୣ	୦ୡ୲ିୟቁ X(Bଵ − b)	ቃ + b        (Eq. 2-10) 
 
 
Figure 2-11. Casson plot showing how to determine A2, the cube root of the corrected 
yield stress, ૌܡ, to a standard hematocrit of 45 %, and B2, the cube root of the 
corrected Casson constant, k, to a standard hematocrit of 45 %   
 
 
After cubing and then substituting the calculated yield stress and the Casson 
constant into (eq. 2-4), the corrected WBV to a standard hematocrit of 45 % could be 
simply achieved for any shear rate range: 
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2.3.2 The Comparison of a New Hematocrit-Correction Model to the 
Matrai’s Model 
In order to investigate the validity of a new hematocrit-correction model, 
three different blood samples were collected from three volunteers. The blood 
samples were adjusted to 25, 30, 35, 40, 45, 50, 55, and 60 % of hematocrits, and 
their WBVs were measured using SCTV. Plasma viscosity was also measured to 
correct the measured WBV using the Matrai’s model as mentioned in (eq. 2-1). 
The measured WBVs for the adjusted hematocrit values were corrected to a 
standard hematocrit using both the Matrai’s model and a new model. The calculated 
sum of errors for sample A, B, and C are shown in Figs. 2-12 to 2-17. 
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Figure 2-12. Calculated sum of the error for different shear rates after measured 
WBVs were corrected to a standard hematocrit of 45 % using the Matrai’s model [45] 
(Sample A) 
 
 
Figure 2-13. Calculated sum of the error for different shear rates after measured 
WBVs were corrected to a standard hematocrit of 45 % using a new hematocrit-
correction model (Sample A) 
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Figure 2-14. Calculated sum of the error for different shear rates after measured 
WBVs were corrected to a standard hematocrit of 45 % using the Matrai’s model [45] 
(Sample B) 
 
 
Figure 2-15. Calculated sum of the error for different shear rates after measured 
WBVs were corrected to a standard hematocrit of 45 % using a new hematocrit-
correction model (Sample B) 
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Figure 2-16. Calculated sum of the error for different shear rates after measured 
WBVs were corrected to a standard hematocrit of 45 % using the Matrai’s model [45] 
(Sample C) 
 
 
Figure 2-17. Calculated sum of the error for different shear rates after measured 
WBVs were corrected to a standard hematocrit of 45 % using a new hematocrit-
correction model (Sample C) 
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As seen in Figs. 2-12 to 2-17, the corrected WBVs using the Matrai’s model 
showed larger errors than the corrected WBVs using a new hematocrit-correction 
model. In case of the Matrai’s model, the peaks in the error were observed around 
from 30 to 35 % of hematocrit ranges with a maximum error up to about 0.15 and the 
minimum error was shown at around 40 to 45 % of hematocrit. As hematocrit value 
increased, the error also increased larger at low shear rates than high shear rates. 
The corrected WBVs using a new hematocrit-correction model showed 
stable and low errors around from 30 to 50 % of hematocrits over the entire shear rate 
ranges. However, as the hematocrit decreased to 25 %, the error slightly increased. A 
larger increase in error was observed over 50 % of hematocrits.  
The increased error at the hematocrit value over 50 % could be explained by 
the relations between the cube root of the yield stress and hematocrits on the Casson 
plot. Figure 2-18, referred from Merill’s results [29], shows that when the hematocrit 
increased over 50 %, the yield stress lost its linearity with hematocrit, and the 
curvature in the correlation was observed over hematocrit value of about 50 % [29]. 
Thus, the linear correlation between the yield stress and hematocrit described using 
the Casson model was not valid over about 50 % of hematocrit. 
For the errors shown at 25 % of hematocrit, it might be due to the 
sedimentation of red blood cells, occurring dominantly at the low concentration of 
red blood cells during WBV measurement. In Fig. 2-8, the data below the linear 
regression curves at 25% of hematocrit value were deviated in a similar manner for 
the three samples. Thus, the sedimentation might have caused the error in 
61 
 
determining the yield stress and the Casson constant during WBV measurement, 
which led to an increase of the error when WBV was corrected to a standard 
hematocrit. 
   
 
 
Figure 2-18. Casson plot showing the relations between the cube root of the yield 
stress, ૌܡ, versus hematocrit, referred from Merill et al.’s work [29] 
 
 
The deviation between the experimentally measured WBV at 45% 
hematocrit and the corrected WBVs according to the two variables (i.e. hematocrit 
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and shear rate) were calculated to visually display the accuracy of the corrected 
results. 
Firstly, for the Matrai’s model, the positive and negative deviations of the 
corrected WBVs from the measured WBV at 45 % hematocrit were calculated. The 
results are listed in Tables 2-2 to 2-4, and also plotted to a scatter diagram with 
connecting lines for different shear rate as shown in Figs. 2-19 to 21. 
Note that since a new model was shown to be valid from 30 to 50 % of hematocrit 
ranges, the comparison of a new model with the Matrai’s model was performed 
within the hematocrit ranges from 30 to 50 %. 
As seen in Tables 2-2 to 2-4, the corrected WBVs using the Matrai’s model 
showed under-estimated results at high hematocrits (> 45 %) and low shear rates, and 
over-estimated results at high hematocrits (> 45 %) and high shear rates. At low 
hematocrits (<35%), the corrected WBVs varied according to the change of shear 
rates. From Figs. 2-19 to 2-21, the maximum positive deviation was 27.6 % from the 
measured WBV at 45 % hematocrit, whereas the maximum negative deviation was -
37.5 %. 
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Table 2-2. Corrected WBVs using the Matrai’s model [45] (Sample A) (cP) 
Shear rate 
(1/s) 
Hct 30 % Hct 35 % Hct 40 % Hct 45 % Hct 50 % 
Viscosity 
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity 
(cP) 
1 19.57 29.81 30.14 27.02 23.67 
2 12.99 18.82 19.14 17.74 16.18 
4 9.35 12.84 12.99 12.35 11.66 
5 8.55 11.53 11.63 11.13 10.61 
6 7.98 10.62 10.69 10.28 9.86 
10 6.75 8.65 8.62 8.39 8.19 
20 5.65 6.91 6.79 6.68 6.65 
40 4.94 5.83 5.64 5.59 5.64 
50 4.77 5.57 5.36 5.32 5.40 
60 4.65 5.38 5.16 5.13 5.22 
80 4.48 5.12 4.89 4.87 4.97 
100 4.37 4.95 4.71 4.70 4.81 
150 4.20 4.70 4.44 4.44 4.56 
200 4.03 4.53 4.28 4.28 4.41 
250 3.88 4.37 4.16 4.17 4.31 
300 3.77 4.25 4.07 4.08 4.25 
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Table 2-3. Corrected WBVs using the Matrai’s model [45] (Sample B) (cP) 
Shear rate 
(1/s) 
Hct 30 % Hct 35 % Hct 40 % Hct 45 % Hct 50 % 
Viscosity 
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity 
(cP) 
1 28.86 36.83 29.47 26.79 22.70 
2 18.28 22.43 18.73 17.58 15.44 
4 12.69 14.77 12.74 12.23 11.08 
5 11.49 13.13 11.42 11.02 10.07 
6 10.66 12.00 10.50 10.17 9.35 
10 8.86 9.56 8.49 8.30 7.75 
20 7.27 7.45 6.71 6.60 6.28 
40 6.28 6.15 5.60 5.52 5.32 
50 6.05 5.84 5.33 5.26 5.08 
60 5.88 5.62 5.14 5.07 4.91 
80 5.64 5.32 4.87 4.81 4.68 
100 5.49 5.12 4.70 4.64 4.53 
150 5.25 4.82 4.43 4.38 4.29 
200 5.03 4.63 4.28 4.23 4.15 
250 4.85 4.46 4.12 4.11 4.05 
300 4.72 4.33 4.01 4.00 3.96 
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Table 2-4. Corrected WBVs using the Matrai’s model [45] (Sample C) (cP) 
Shear rate 
(1/s) 
Hct 30 % Hct 35 % Hct 40 % Hct 45 % Hct 50 % 
Viscosity 
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity 
(cP) 
1 19.57 29.81 30.14 27.02 23.67 
2 12.99 18.82 19.14 17.74 16.18 
4 9.35 12.84 12.99 12.35 11.66 
5 8.55 11.53 11.63 11.13 10.61 
6 7.98 10.62 10.69 10.28 9.86 
10 6.75 8.65 8.62 8.39 8.19 
20 5.65 6.91 6.79 6.68 6.65 
40 4.94 5.83 5.64 5.59 5.64 
50 4.77 5.57 5.36 5.32 5.40 
60 4.65 5.38 5.16 5.13 5.22 
80 4.48 5.12 4.89 4.87 4.97 
100 4.37 4.95 4.71 4.70 4.81 
150 4.20 4.70 4.44 4.44 4.56 
200 4.03 4.53 4.28 4.28 4.41 
250 3.88 4.37 4.16 4.17 4.31 
300 3.77 4.25 4.07 4.08 4.25 
 
 
 
66 
 
 
 
Figure 2-19. Deviations of the corrected WBVs using the Matrai’s model [45] from 
measured WBV at 45 % hematocrit at different shear rates (Sample A) 
 
 
Figure 2-20. Deviations of the corrected WBVs using the Matrai’s model [45] from 
measured WBV at 45 % hematocrit at different shear rates (Sample B) 
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Figure 2-21. Deviations of the corrected WBVs using the Matrai’s model [45] from 
measured WBV at 45 % hematocrit at different shear rates (Sample C) 
 
 
Secondly, for the new hematocrit-correction model, the positive and negative 
deviations of the corrected WBVs from the measured WBV at 45 % hematocrit were 
also calculated. The results are listed in Tables 2-5 to 2-7, and plotted to a scatter 
diagram with connecting lines for different shear rate as shown in Figs. 2-22 to 2-24. 
As seen in Tables 2-5 to 2-7, the corrected WBVs using the new hematocrit-
correction model showed less deviation compared to the measured WBV at 45 % of 
hematocrit over 30 to 50 % hematocrit ranges at the shear rates. From Figs. 2-22 to 2-
24, the maximum positive and negative deviations from the measured WBV at 45% 
hematocrit were 8.5% and -6.7%, respectively, which were about 4 to 6 times lower 
than those at the Matrai’s model. 
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Table 2-5 Corrected WBV using the present model (Sample A) (cP) 
Shear rate 
(1/s) 
Hct 30 % Hct 35 % Hct 40 % Hct 45 % Hct 50 % 
Viscosity 
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity 
(cP) 
1 30.99 33.36 29.90 31.26  30.86 
2 20.19 21.56 19.53 20.34  20.33 
4 13.94 14.77 13.53 14.03  14.20 
5 12.54 13.24 12.17 12.61  12.81 
6 11.54 12.17 11.22 11.61  11.84 
10 9.37 9.82 9.12 9.41  9.68 
20 7.40 7.70 7.23 7.43  7.73 
40 6.16 6.36 6.02 6.17  6.48 
50 5.86 6.04 5.73 5.87  6.18 
60 5.64 5.81 5.52 5.65  5.97 
80 5.34 5.49 5.23 5.35  5.67 
100 5.14 5.28 5.04 5.15  5.47 
150 4.84 4.96 4.75 4.85  5.17 
200 4.67 4.77 4.58 4.67  4.99 
250 4.55 4.65 4.47 4.55  4.87 
300 4.46 4.55 4.39 4.45  4.79 
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Table 2-6 Corrected WBV using the present model (Sample B) (cP) 
Shear rate 
(1/s) 
Hct 30 % Hct 35 % Hct 40 % Hct 45 % Hct 50 % 
Viscosity 
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity
(cP) 
Viscosity 
(cP) 
1 28.86 36.83 29.47 26.79  22.70 
2 18.28 22.43 18.73 17.58  15.44 
4 12.69 14.77 12.74 12.23  11.08 
5 11.49 13.13 11.42 11.02  10.07 
6 10.66 12.00 10.50 10.17  9.35 
10 8.86 9.56 8.49 8.30  7.75 
20 7.27 7.45 6.71 6.60  6.28 
40 6.28 6.15 5.60 5.52  5.32 
50 6.05 5.84 5.33 5.26  5.08 
60 5.88 5.62 5.14 5.07  4.91 
80 5.64 5.32 4.87 4.81  4.68 
100 5.49 5.12 4.70 4.64  4.53 
150 5.25 4.82 4.43 4.38  4.29 
200 5.03 4.63 4.28 4.23  4.15 
250 4.85 4.46 4.12 4.11  4.05 
300 4.72 4.33 4.01 4.00  3.96 
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Table 2-7 Corrected WBV using the present model (Sample C) (cP) 
Shear rate 
(1/s) 
Hct 30 % Hct 35 % Hct 40 % Hct 45 % Hct 50 % 
Viscosity 
(cP) 
Viscosity
(cP)
Viscosity
(cP)
Viscosity
(cP)
Viscosity 
(cP) 
1 27.19 25.83 28.46 27.02  28.56 
2 17.85 17.00 18.55 17.74  18.75 
4 12.43 11.87 12.81 12.35  13.05 
5 11.21 10.71 11.52 11.13  11.76 
6 10.35 9.89 10.61 10.28  10.86 
10 8.44 8.09 8.61 8.39  8.86 
20 6.72 6.46 6.81 6.68  7.05 
40 5.63 5.41 5.66 5.59  5.90 
50 5.36 5.16 5.38 5.32  5.62 
60 5.17 4.98 5.19 5.13  5.42 
80 4.91 4.73 4.91 4.87  5.15 
100 4.73 4.56 4.73 4.70  4.96 
150 4.47 4.31 4.45 4.44  4.68 
200 4.31 4.16 4.29 4.28  4.52 
250 4.21 4.06 4.19 4.17  4.41 
300 4.13 3.99 4.11 4.08  4.33 
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Figure 2-22. Deviations of the corrected WBVs using a new hematocrit-correction 
model from measured WBV at 45 % hematocrit at different shear rates (Sample A) 
 
 
Figure 2-23. Deviations of the corrected WBVs using a new hematocrit-correction 
model from measured WBV at 45 % hematocrit at different shear rates (Sample B) 
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Figure 2-24. Deviations of the corrected WBVs using a new hematocrit-correction 
model from measured WBV at 45 % hematocrit at different shear rates (Sample C) 
 
 
Lastly, Figs. 2-25 to 2-33 show the profiles of the WBVs for the hematocrit-
adjusted blood samples (i.e. 30, 35, 50, 45, and 50 %), the profiles of the WBVs after 
correction using Matrai’s model, and the profile of the WBVs after correction using a 
new hematocrit-correction model, which were plotted for comparison for Sample A, 
B, and C.  
Comparing Figs. 2-26 and 2-27, 2-29 and 2-30, 2-32 and 2-33, the validity 
and difference between the hematocrit-correction models were clearly observed. 
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When the measured WBVs for different native hematocrits as shown in Figs. 2-25, 2-
28, and 2-31, were corrected to a standard hematocrit of 45 %, the WBV profiles by 
the new hematocrit-correction model were thoroughly plotted close to the WBV 
profile of 45 % hematocrit in Figs. 2-27, 2-30, and 2-33, while those by the Matrai’s 
model stayed with large deviations from the WBV profile of 45% hematocrit in Figs. 
2-26, 2-27, and 2-32.  
 
 
 
Figure 2-25. Measured WBV profiles of original hematocrit-adjusted bloods (i.e. 30, 
35, 50, 45, and 50 %) before the correction to a standard hematocrit of 45 % (Sample A) 
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Figure 2-26. Corrected WBV profiles using the Matrai’s model [45] (Sample A) 
 
 
 
Figure 2-27. Corrected WBV profiles using a new hematocrit-correction model 
(Sample A) 
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Figure 2-28. Measured WBV profiles of original hematocrit-adjusted bloods (i.e. 30, 
35, 50, 45, and 50 %) before the correction to a standard hematocrit of 45 % (Sample B) 
 
 
Figure 2-29. Corrected WBV profiles using the Matrai’s model [45] (Sample B) 
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Figure 2-30. Corrected WBV profiles using a new hematocrit-correction model 
(Sample B) 
 
 
Figure 2-31. Measured WBV profiles of original hematocrit-adjusted bloods (i.e. 30, 
35, 50, 45, and 50 %) before the correction to a standard hematocrit of 45 % (Sample C) 
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Figure 2-32. Corrected WBV profiles using the Matrai’s model [45] (Sample C) 
 
 
Figure 2-33. Corrected WBV profiles using a new hematocrit-correction model 
(Sample C) 
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2.4 Limitations 
The validation of the new hematocrit-correction model in correcting the 
measured WBV at native hematocrit to a standard hematocrit of 45 % was achieved 
with less errors and deviations over a wide range of shear rates than the Matrai’s 
model. Furthermore, the new model does not require the measurement of plasma 
viscosity. In general, once the yield stress and the Casson constant could be obtained 
by either the SCTV or any other viscometers, the corrected WBV could be calculated 
using the proposed equation given in the present study. 
Even though the valid range of the new hematocrit-correction model was 
limited to hematocrit values of 30 to 50 %, which did not cover a whole range of 
hematocrit (i.e. from 0 to 100 %), it could be utilized in clinical experiments, where 
normal hematocrit ranges of men and women are about 36 to 45 % and about 39 to 
50 %, respectively. 
Further research is recommended to determine the specific characteristics 
and values of Constant C1, the intersection of the two linear lines that indicate the 
cube root of the yield stress and the cube root of the Casson constant as a function of 
hematocrit on the Casson plot. Thus, one needs to investigate further clinical 
applicability of the new model whether or not it could show a similar intersection for 
people with different levels of plasma viscosity, caused by different concentration 
levels of macro-molecules such as plasma proteins in blood plasma. 
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CHAPTER 3: A NEW ON-LINE CONDUCTANCE CELL FOR HEMATOCRIT 
MEASUREMENTS 
3.1 Motivations and Literature Survey on Hematocrit Measurement 
Hematocrit is defined as the percentage of whole blood volume occupied by 
red blood cells [56, 57], representing the amount of oxygen in the whole blood [58, 
59]. It is one of the important blood properties to assess the oxygen delivery in 
relation to ischemic diseases [60]. Recently, it is also considered as a marker of 
oxygen carrying capacity of the blood associated with whole blood viscosity to assess 
the mortality risk of both cardiovascular, cerebral, and kidney diseases [10, 61-63]. 
Since the red blood cells contain hemoglobin molecules, the oxygen-delivery 
capacity to a tissue at a constant flow rate is higher if the hematocrit of the perfusing 
blood is higher. However, increased hematocrit results in a nonlinear increase of 
blood viscosity (or flow resistance), and thus the flow rate of blood might be 
decreased, reducing the amount of blood perfusion to a given tissue. In order to 
express the relations between WBV and hematocrit, a parameter known as the oxygen 
delivery index (ODI) is being used, which is defined as the ratio between hematocrit 
and WBV [1, 3].  
 
ODI = 	 ୌୣ୫ୟ୲୭ୡ୰୧୲	୆୪୭୭ୢ	୴୧ୱୡ୭ୱ୧୲୷		                         (Eq. 3-1) 
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According to Kaplan-Meier survival analysis performed by Kenyeres et al., 
ODI showed significant negative correlation with the frequency of hospital 
admissions (r = -0.377, p = 0.03), which stated the significance of ODI as a risk 
factor of cardiac death in coronary heart disease [3, 10]. 
In order to quantify an optimum balance of ODI, it is required not only to 
automatically measure the profile of WBV using SCTV but also to determine 
hematocrit simultaneously.  
Several methods to determine hematocrit values in whole blood have been 
suggested, mainly with an electrical method and a light-emitting method.  
The bioelectrical impedance technique has been utilized to determine the 
conductivity of blood [57, 64-72], which depended on plasma resistance, red cell 
intracellular resistance, red cell membrane capacitance, and erythrocyte 
sedimentation [57, 72]. Due to the difficulties in measuring these parameters, the 
bioelectrical impedance technique could not be done accurately [57, 64-66, 69, 72]. 
In case of the plasma resistance, a number of studies have employed an alternating 
voltage signal to minimize an electrolyte effect on the plasma resistance [57, 72]. 
Such an approach was mostly carried out at a single frequency in a range of 1 kHz -1 
GHz [72-74] in a sine-wave form. Even though the sine-wave single frequency 
method improved the measurement accuracy of the plasma resistance, the electrolyte 
concentration still affected the resistivity of plasma, but less than the DC voltage 
signal [72, 75]. Dual or triple frequencies were also utilized to simultaneously 
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measure the plasma resistance, the red cell intracellular resistance or/and the red cell 
membrane capacitance [57, 72]. 
Recently, analytical equations have been developed to take into account the 
volume or conductance of the cellular particles in the conductance measurement [64, 
66, 72, 76]. Even though these mathematical models were well-developed, the final 
equation for the conductivity of whole blood still contains four variables which must 
be determined experimentally by independent methods.  
ρ = 	 ቀ
౨
౨భቁି	ଵ
		ቀ ౨౨భቁି	ଵ	ା	୤		
             (Eq. 3-2) 
where r/rଵ is the ratio of the specific resistance of suspension to that of the 
mixture medium, ρ is the volume fraction occupied by suspended particles, and f is a 
form factor which depends on the axial ratio of suspended ellipsoids [66, 72, 77]. 
However, since these studies were conducted in a stationary flow state, erythrocyte 
sedimentation could cause error in the measurement of the conductivity of whole 
blood [57, 72]. There was no study to report the conductivity measurement of whole 
blood which was moving at a constant velocity to prevent the erythrocyte 
sedimentation. 
Thus, this chapter was aimed to propose a new on-line device using a 
conductance method, which can automatically measure hematocrit and can be easily 
integrated with the SCTV, specifically to propose a new on-line conductivity cell to 
measure the hematocrit of whole blood using a low-frequency bipolar square-wave 
voltage signal to overcome the aforementioned difficulties without the erythrocyte 
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sedimentation problem. 
 
3.2 Methods 
3.2.1 Experimental Setup 
The present experimental setup is given in Fig. 3-1 and 3-2, which consisted 
of a syringe pump, a vacutainer, a temperature-controlled dry bath, short and long 
needles, a conductivity cell, a power supply, and a signal analyzer. A plain vacutainer 
(4 mL) filled with whole blood sample was placed at the temperature-controlled dry 
bath. Whole blood samples with three different hematocrits were used to check the 
validity of the present method. The syringe pump was used to pressurize air in the 
vacutainer so that the whole blood was pushed out by the compressed air and 
introduced into the conductance cell. Both short 21G (3.81 cm in length) and long 
18G (15.24 cm in length) needles were inserted into the vacutainer for air infusion 
and blood outflow, respectively. As the whole blood moved into the conductance cell, 
the electrical resistivity of the whole blood was determined by applying a square-
wave voltage signal across the conductance cell and measuring the resulting current 
between the two electrodes in the cell. 
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The conductance cell was developed as a tubular assembly (0.635 cm in 
diameter) as shown in Fig. 3-3 and Fig. 3-4, which had two annular 304L stainless-
steel electrodes separated by a polystyrene barrier so that whole blood could continue 
to flow during conductivity measurements. One of the reasons why the present 
method used the conductance cell with continuously moving blood was to minimize 
the measurement error that could have been caused by the sedimentation of cells in 
whole blood [64]. The blood volume inside the cell was around 1.2 mL. The 
conductance cell was designed as a disposable unit so that the cell did not have to be 
cleaned after each test. In addition, the cell was placed into a specially prepared 
holder (as shown in Fig. 5-3) for electrical insulation, easy connection and removal. 
 
 
 
Figure 3-3. Photograph of conductance cell placed in a holder. 
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(a) Sectional View 
  
 
(b) 3D view 
Figure 3-4. Sectional (a) and 3D (b) drawings of conductance cell 
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3.2.2 Description of Power Supply and Signal Analyzer 
Figure 3-5 shows the detailed schematic circuit diagram for the present 
conductance cell to generate a bipolar square-wave voltage signal and measure the 
resulting current between the two electrodes at the cell. The applied sensing voltage 
was less than 50 mV so that the reduction-oxidation effect could be minimized on the 
electrode surfaces. Furthermore, a bipolar voltage was used to minimize the effect of 
polarization on the cell. The applied voltage had 100-mV peak-to-peak square-wave 
signal which was centered at zero. In order to achieve the minimal decay in the 
current waveform due to the dielectric effect of whole blood, a frequency of 5 kHz 
was employed. The current waveform was corrected by incorporating a peak-reading 
circuit. Since the cell membrane and the intracellular water became conductive when 
the frequency was above 100 kHz [57], the present study used a frequency of 5 kHz, 
where the resistance of erythrocytes remained constant over time. 
Some conductance meters used a sine-wave voltage signal at various 
frequencies [57, 72, 78]. In this case, it was not easy to obtain a stable amplitude 
voltage signal. In the present study, a CMOS Schmitt trigger relaxation oscillator 
provided the square-wave voltage signal which was clipped by positive and negative 
supply voltages. The supply voltages were set by precision 2.5-V Zener diodes. The 
square-wave signal was scaled to 100 mV with a precision divider and a unity gain 
follower to provide a low-impedance source which drove the conductance cell. 
An op-amp circuit was incorporated to provide 5-mV peak output from 
several μA input current. A scaling switch was also employed to double or triple the 
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mV peak output to accommodate a higher resistivity of blood as in polycythemia vera 
[79, 80], where hematocrit can increase beyond 60%. 
A precision rectifier was used as an absolute magnitude converter to convert 
the bipolar square wave to a DC value which was proportional to an input current. 
The diodes were placed within an op-amp feedback loop to avoid an approximate 0.7-
V drop normally found with a rectifier. A digital meter with a 9-cm digital LCD was 
utilized with a reading range of 0-199.9 μA at the conductance cell. 
 
 
 
Figure 3-5. Schematic diagram of the circuit in the present conductance cell 
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3.2.3 Sample Preparation 
Normal whole blood of 450 mL anticoagulated with K2 EDTA was obtained 
from Lampire Biological Laboratories, PA, USA, which was drawn from a healthy 
donor. Since it was reported that other types of anticoagulants (i.e. heparin and 
sodium citrate) were found to influence the accurate measurement of the electrical 
impedance of blood, EDTA was chosen in the present study [72]. 
In order to investigate the relationship between hematocrit and electrical 
conductivity, the hematocrit was varied over a range from 20 to 65% which were 
considered to be the physiological minimum and maximum values, respectively, in 
human [81-84]. After being mixed gently and homogeneously, the whole blood 
sample of 450 mL was transferred to 10-mL transparent containers and centrifuged 
(VanGuard V6500, Hamilton Bell Co.) with a relative centrifugal force of 1,200 G for 
15 min. Then, a portion of plasma was either removed or added from the centrifuged 
containers to produce blood samples at different hematocrits. The hematocrit-adjusted 
whole blood samples were then transferred to 4-mL vacutainers for the conductivity 
measurement. In order to check the reliability of the present methods, 20 identical 
whole blood samples were prepared for repeated measurements for ten different 
hematocrit cases (i.e., 20, 25, 30, 35, 40, 45, 50, 55, 60, and 65%).  
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3.2.4 Experimental Procedure 
Conductivity, G (mS), can be determined from the inverse of resistance 
according to the Ohm’s law [76]. 
G = 	 ଵୖୡୣ୪୪	                              (Eq. 3-3) 
where Rୡୣ୪୪  is the resistance of the conductance cell filled with a test fluid. The 
specific conductivity C (mS/cm) is defined as  
C = G		x		 ୢ୅	                            (Eq. 3-4) 
where d is the distance between two electrodes (i.e., 3 mm), and A is the total contact 
surface area of the two electrodes. Note that the ratio of the distance between the two 
electrodes to the electrode surface area, d/A, is defined as the cell constant, K (cmିଵ):  
K = 	 ୢ୅                               (Eq. 5-5) 
However, the equation of the cell constant does not take into account the 
effects of both fringe electric field and interfacial resistances on the conductivity. 
Since it is often difficult to calculate the cell constant including these effects, the cell 
constant, K, is determined through a separate calibration procedure using a 
conductivity-standard liquid with a known electrical conductivity [76, 
85].Considering the measurement range of the present conductance cell, two different 
conductivity-standard solutions, 3 mS/cm (Conductivity/TDS Standard, 1534 ppm as 
NaCl) and 10 mS/cm (5400 ppm as NaCl) (both from Ricca Chemical, TX), were 
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used for the calibration of the cell constant [76, 85, 86].  
The blood samples were thoroughly mixed using a roller mixer to insure the 
homogeneity of the samples and placed in a vacutainer sample holder at room 
temperature (25±0.5ºC) [74]. Then, a syringe pump was used to pressurize the air in 
the vacutainer so that the whole blood could be pushed out to the conductance cell at 
a constant flow rate of 1.2 mL/min, where the effect of the erythrocyte sedimentation 
on the conductivity of blood was negligible as shown below. While blood was 
moving through the cell, the resulting current between the two electrodes at the cell 
was measured with a signal analyzer and displayed on a digital LCD [64, 87, 88]. 
Hematocrit was also determined using a microcentrifuge for comparison with the 
results obtained from the present conductance cell.  
In order to investigate the effects of flow rate on the blood conductivity 
measurement, blood samples at three different hematocrits of 25, 45, and 60 % were 
used, each at five different flow rates of 0.5, 1.2, 1.8, 2.5, and 3 mL/min at the 
conductance cell with ID of 0.635 cm. 
Prior to each conductivity measurement, the calibration of the electrical 
circuit was performed by inserting a 1,000-ohm resister (±1% tolerance), confirming 
that the power supply and signal analyzing unit were in normal operation without any 
effects of noise, interference or disconnection on the circuit. Then, the hematocrit of 
each blood sample was measured using the aforementioned microcentrifuge before 
and after the measurement of blood resistance using the conductance cell, not only to 
investigate the relationship with the present resistance method but also to check 
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whether or not the hemolysis of erythrocytes occurred in whole blood sample due to 
the contact with electrical current and/or the relatively high flow velocity of blood 
(i.e., up to 0.6 cm/s) inside the conductance cell [57, 64]. 
 
3.2.5 Statistical Analysis 
Statistical analysis was performed using linear regression analyses to 
evaluate the correlations and standard error between the conductivity values obtained 
with the present conductance cell and the conventional microcentrifuge method. A p 
value less than 0.05 is considered statistically significant, which is the same as having 
a 95% confidence interval. Analysis of variance (ANOVA) was also performed to 
determine if the conductivity changed according to flow rates. 
  
3.3 Results and Discussion 
The circuit used in this study, as shown in Fig. 3-5, was fabricated in a 
printed circuit board, as shown in Fig. 3-6 and the resultant signal was generated as 
shown in Fig. 3-7.  
From the circuit diagram in Fig. 3-5, CMOS Schmitt trigger circuit 
generated an operating signal of 5 kHz. Figure 3-7(a) shows the waveform at Point A 
in Fig. 3-5. In order to assure that the applied waveform had a duty cycle of exactly 
50%, the above signal was fed into a counter. The output of the counter at Point B is 
shown in Fig. 3-7(b). 
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Since the amplitude of this square wave was dependent upon power supply 
voltages, a circuit comprising Zener diodes and a precision reference diode were used. 
The aforementioned square-wave signal was used to alternately ground each end of 
the diode to establish an accurate bipolar signal. Both the anode (Light line) and 
cathode (Dark line) voltages at Point C are shown in Fig. 3-7(c). The voltages shown 
in Fig. 3-7(c) were summed and set to 100-mV peak-to-peak amplitude by using 
resistors and the unity gain amplifier. The signal at Point D is shown in Fig. 3-7(d). 
 
 
 
Figure 3-6. Photograph of the fabricated circuit in a printed circuit board used in the 
present study 
The op-amp converted the resulting current of the conductance cell into a 
voltage with three switchable gain settings. In the 1X position, the output meter was 
read directly in μA. In the 2X and 3X positions, the meter reading was divided by 2 
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and 3, respectively. In the 1X position, the resulting saw-tooth signal at Point E is 
shown in Fig. 3-7(e). The rectifier circuit was comprised to obtain the absolute 
magnitude of the cell current. Switch SW2 was used to select which signal was to be 
displayed on the voltmeter between average and peak signals. The waveform of the 
average value at Point F is shown in Fig. 3-7(f). The digital LCD voltmeter contained 
a filter to display the average value (i.e., 1.21 V) as shown by an index line in the 
figure, which was equal to 121-μA cell current. 
The peak-value circuit measured the peak value of the current about 10 μS 
after the cell current changed its direction. At point G, the horizontal dark line trace 
shown in Fig. 3-7(g) was a DC level which was superimposed on the rectified signal 
of Fig. 3-7(f). In this case, the peak value was shown as 1.77 V, which was equal to 
177-μA peak cell current.  
As shown in Fig. 3-7(f), the stable resulting current was achieved from a 
square-wave voltage signal, and the resulting current was directly proportional to the 
electric conductivity of blood. The measurements were found to be stable and noise 
free as shown in Figs. 3-7(a) to (f) and did not exhibit variations from the 
sedimentation of red blood cells as long as the whole blood kept moving through the 
horizontally-positioned conductance cell. 
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(a) 
 
 
(b) 
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(d) 
96 
 
 
(e) 
 
(f) 
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(g) 
Figure 3-7. Signals generated from the circuit in the present conductance cell. (a) 
Point A; (b) Point B; (c) Point C; (d) Point D; (e) Point E; (f) Point F; and (g) Point G. 
 
 
The cell constant, K, was determined with conductivity-standard liquids 
which had known electrical conductivities. From eqs. (3-3)-(3-5), the cell constant, K, 
can be expressed by the following equation: 
K	 = 			 Rୡୟ୪			X					Cୡୟ୪                      (Eq. 3-6) 
where Rୡୟ୪	 is the resistance of the cell measured at a specific electrode separation 
when the cell was filled with calibration liquid [76], and Cୡୟ୪  was the known 
electrical conductivity of the conductivity-standard fluid. 
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For the two conductivity-standard fluids of 3 and 10 mS/cm, the cell 
constants were found to be 18.520±1.867 and 18.505±1.013	cmିଵ, respectively. The 
standard deviation in the case of the 3-mS/cm standard fluid was about 1.8 times 
larger than that for the case of 10-mS/cm. This difference can be attributed to the 
resolution of LCD reading with one decimal point, which was ±0.5% (for 3,000-
μS/cm standard fluid) and ±1% (for 10,000-μS/cm standard fluid) deviations from the 
respective mean values. The mean value of the cell constant from the two calibration 
tests with two conductivity-standard fluids was 18.513±1.464 cmିଵ. 
Hematocrits measured for each blood sample before and after each 
conductivity measurement did not give any significant difference between the two 
hematocrit values (p > 0.05), confirming that no hemolysis occurred during the 
present conductivity measurement procedure [57, 64]. 
Using the cell constant, K, obtained from the aforementioned calibration 
procedure, the current was measured for each blood sample using the present 
conductivity cell, and then the conductivity of whole blood was calculated. Figure 3-
8 shows the values of measured current (closed square) and specific conductance 
(open triangle) versus hematocrit obtained from microcentrifuge over a range of 
hematocrit. The measured current was found to decrease linearly with increasing 
hematocrit.   
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Figure 3-8. Output current and specific conductance measured at the present 
conductance cell over a range of hematocrits obtained with a microcentrifuge. C =  
specific conductance (mS/cm). 
 
 
Figure 3-9 shows changes in the conductivity of blood as a function of flow 
rates from 0.5 to 3.0 mL/min (i.e., from 0.027 to 0.16 cm/s) inside conductance cell 
for three different hematocrit samples of 25, 45, and 60 %. The specific conductance 
for the case of 25%-hematocrit sample was 8.326 mS/cm at a flow rate of 0.5 mL/min. 
As the flow rate increased to 1.2 mL/min, the specific conductance increased to 8.933 
mS/cm. Further increase in the flow rate up to 3.0 mL/min almost did not change the 
specific conductance. Similar trends were observed for higher hematocrit samples of 
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45 and 60%, although the rate of change of the specific conductance as the flow rate 
increased from 0.5 to 1.2 mL/min was much smaller compared to that in the case of 
25% hematocrit. 
 
 
Figure 3-9. Specific conductivity measured from the present method using a 
conductance cell versus flow rates for three different hematocrits 
 
 
The present study proposed a new method to measure the conductivity of 
whole blood. A conductance cell was fabricated to generate a low-frequency bipolar 
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square-wave voltage signal between two cylindrical electrodes. By the utilization of 
alternating bipolar signal, the electrolyte effect which altered the resistivity of plasma 
could be reduced, and hence the accuracy of conductance measurement was increased.  
By applying a relatively low-frequency voltage signal (i.e., 5 kHz), the 
resistance of blood was able to remain constant without a decay in the current 
waveform due to dielectric effects of blood cells, so that the red blood cells could be 
considered as a non-conductive substance. The capacitive effect of the cell membrane 
could be minimized in response to the applied square-wave signal which provided a 
constant alternating voltage [76, 85, 86]. The difficulty often caused by the 
sedimentation of red blood cells was minimized in the present conductance cell as the 
whole blood continuously moved through the cylindrical electrodes [64]. 
Linear regression analyses of 200 data points (i.e. ten different hematocrits 
and 20 repeated runs for each hematocrit) were conducted to calculate the correlation 
and standard error between the conductivities measured from the present method and 
hematocrits determined from microcentrifuge. The coefficient of correlation and R 
value in Table 1 showed an excellent linear relationship between the two methods, 
and the variability in the data set was small as manifested by R2 = 0.989 (p < 0.001). 
The resulting equation after the regression analysis can be given by the following 
equation:  
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C = 12.561 − 0.1527	Hct                       (Eq. 3-7) 
where C is the specific conductance (mS/cm) , and Hct is the hematocrit of whole 
blood (%). 
Table 3-1 also shows several correlations between the impedance and 
hematocrit. Cha et al. [57] reported an equation based on the data measured at room 
temperature, using linear, exponential, and Maxwell-Fricke expressions [57, 72, 77, 
89, 90]. Considering the accuracy of the equations with the coefficient of correlation 
R and standard error SE, the present model, also shown at the bottom of Table 3-1, 
was found to have the least standard error with a similar coefficient of correlation 
compared to the previous correlations [57, 72, 77, 89, 90]. This could be attributed to 
the square-wave voltage signal, which minimized the errors from the electrolyte 
effect on the plasma resistance and the capacitive behavior of red cell membrane, as 
well as the error associated with the erythrocyte sedimentation 
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Table 3-1. Previous correlations to determine hematocrit as a function of impedance 
and the new correlation proposed by the present study 
Models 
Coefficient of 
Correlation, R 
SE
Maxwell-Fricke 
[57, 72, 77, 89, 90] 
Hct = 100	 ∙ 	ቆ1 − 149.1R୮ + 107.4ቇ 0.984 
1.7
5 
Exponential 
[57, 72, 77, 89, 90] Hct =
100
2.98	 ∙ 	 ln ൬
R୮
43.0൰ 0.981 
1.8
6 
Linear 
[57, 72, 77, 89, 90] Hct = 100	 ∙ 	ቆ
R୮ + 22.5
425.5 ቇ 0.945 
3.1
5 
Dual-frequency 
[57] Hct = 100	 ∙ 	 ൤0.142 ∙ ln(
R୮
R୦) + 0.155 ∙ ln(X୦) − 0.157൨ 0.989 
1.4
1 
Square wave 
[Present study] 
Hct = −	 10015.27	 ∙ 	
K
Rୱ୯ + 82.259 0.989 
1.0
1 
* SE is standard error, R୮ is the resistance of plasma measured at a low frequency 
below 100 kHz, R୦  is the resistance at a high frequency of 1 MHz, X୦  is the 
reactance measured at a high frequency of 1 MHz, Rୱ୯ is the resistance measured 
using square-wave voltage signal, and K is the cell constant. 
 
In measuring the blood conductivity of whole blood, the electrical resistance 
was found to increase with the sedimentation of erythrocyte [91]. The current 
measured from the present conductance cell was found not stable when whole blood 
was stationary, but continuously decreased with time in spite of the horizontal design 
of the conductance cell. The observed instability could be attributed to the 
sedimentation red blood cells. The effect of the sedimentation on the resistance of 
blood affected the conductance measurement at a small flow rate as manifested in Fig. 
104 
 
3-9, where the specific conductance value had a minimum value at the minimum flow 
rate of 0.5 mL/min for the case of 25%-hematocrit sample and reached an asymptote 
only after the flow rate increased above 1.2 mL/min (i.e., 0.06 cm/s). Any cell 
geometry other than the horizontal cylindrical electrodes could result in the over-
estimation of conductivity due to the sedimentation of erythrocytes [64]. 
The statistical estimation with ANOVA provided the threshold flow where 
the erythrocyte sedimentation affected the conductivity of blood to be below 1.2 
mL/min. For flow rates less than 1.2 mL/min, the measured conductivity was much 
smaller than those obtained at a flow rate of 1.2 mL/min or greater (p = 0.048).  
The effect of flow on the conductivity of the blood can be qualitatively 
explained by the orientation and deformation of red blood cells [87, 88]. When blood 
moves through a cylindrical tube, the shear stress produced from the motion of blood 
orients the red blood cells such that their long axes align parallel to the direction of 
the blood flow. The pathway of a low-frequency AC could alter the orientation and 
alignment of the red blood cells. Consequently, the electrical conductivity in the flow 
direction of blood could increase [87, 88]. However, in the present study, such an 
effect on the conductivity of blood could be minimized by applying a bipolar square-
wave voltage signal not to the direction of flow but to the whole volume of blood. 
The results given in Fig. 3-9 indicate that the on-line measurement of 
hematocrit is feasible. For example, when a blood sample is drawn from a patient, 
hematocrit could be measured at site if the present conductance cell is attached 
between the outlet of a needle and a syringe. In addition, hematocrit could be 
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measured in a capillary tube viscometer if the conductance cell is inserted at the 
supply line of blood sample connected to the viscometer [41, 57]. 
 
3.4 Limitations 
A new on-line conductance cell might have limitations in measuring 
hematocrit accurately for blood samples with impaired blood cells by hemolysis or 
diseases such as sickle-cell disease, sphyrocytosis, etc. 
The accuracy of the current conductance method was achievable as we 
avoided the behaviors of red cells to become conductive or/and capacitive by 
applying specific signals. However, if red cells are physically damaged, it has a doubt 
whether or not the principles of the current method could be applied properly for an 
accurate measurement of hematocrit, which requires further clinical trials. 
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CHAPTER 4: PLASAMA DISCAHRGE TREATMENT TO IMPROVE 
HEMORHEOLOGYCAL PROPERTIES 
4.1 Motivations and Literature Survey on Reduction of Blood Viscosity 
There are a number of variables for the WBV, which include hematocrit, 
plasma proteins (i.e., fibrinogen, immunoglobulin, and albumin), total cholesterol, 
low-density-lipoprotein (LDL) cholesterol, high-density-lipoprotein (HDL) 
cholesterol and triglyceride [1, 18, 28]. In addition, the aggregation and deformability 
of erythrocytes critically affect the WBV [18, 92].  Since both the plasma proteins 
and LDL molecules influence the aggregation of erythrocytes [8, 13, 93, 94], it is 
important to keep both levels within the respective normal ranges. For example, lipid-
lowering statin drugs have been widely used to keep the LDL cholesterol within the 
normal range (i.e., 62-130 mg/dl) [95-102]. Statins are powerful cholesterol-lowering 
drugs in clinical practice and have a life-saving potential in properly selected patients, 
particularly those with severe hyperlipidemia and atherosclerotic disease [103, 104]. 
Results from randomized clinical trials have demonstrated a decrease in congested 
heart diseases (CHD) and total mortality, reductions in myocardial infarctions, 
revascularization procedures, stroke, and peripheral vascular disease [103, 105]. 
However, statins are prescribed for less than half of the patients who should receive 
this therapy, unfortunately, because fear of liver and muscle toxicity, a side effect 
which remains a major impediment to the appropriate use of these drugs [106, 107]. 
In recent years, many new medical applications, including the sterilization of 
living tissue without damage, blood coagulation, the induction of apoptosis in 
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malignant tissues, and the modulation of cell attachment are being developed utilizing 
non-thermal plasma discharges in atmospheric pressure [108-116]. It was 
demonstrated that selective coagulation of fibrinogen, which is one of the major 
viscosity determinants in blood, could be induced by the application of dielectric 
barrier discharges (DBD) in air [108]. Hence it is hypothesized that the 
hemorheological properties of blood may be improved by lowering the levels of 
fibrinogen or/and LDL molecules in blood plasma through electrical plasma-assisted 
coagulation and the subsequent filtration of the coagulated particles from the treated 
blood plasma. Hence, the objective of the present chapter was to investigate the 
feasibility of reducing whole blood viscosity through two types of electrical plasma 
treatment, dielectric barrier discharge (DBD) and corona discharge, of blood plasma 
and subsequent filtration. 
 
4.2 The Effect of DBD Treatment on Blood Viscosity 
4.2.1 Methods 
The DBD system used in the present study was identical to the one used by 
Kalghatgi et al. [108], which was atmospheric pressure dielectric barrier discharge 
and is illustrated in Figs. 4-1 and 4-2. The DBD system was operated with one 
dielectric-covered powered electrode and the other grounded electrode. Discharge 
was ignited when the powered electrode approached the surface of the sample to be 
treated at a distance of less than 3 mm, the phenomenon which depended on the 
waveform, duration, and polarity of the driving voltage [109]. A pulsed high voltage 
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of 35kV (peak to peak) with alternating polarity at 1 kHz frequency was applied 
between the quartz insulated copper electrode and the surface of the sample (blood 
plasma) to generate DBD. The power applied to the present DBD system was 
analyzed by measuring the current passing through the discharge gap and the voltage 
drop in the gap when the discharge was generated. The current and voltage signals 
were acquired and recorded by a two-channel digital phosphor oscilloscope (DPS) 
(TDS5052B, 500 MHz bandwidth, 5 GS/s sample rate, Tektronix, Inc). The surface 
power density which corresponded to the applied power was around 1.5 W/cm2 [108, 
109, 117]. 
 
 
 
Figure 4-1. Application of DBD to a blood plasma sample 
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composed of a 25-mm-diameter copper rod inserted into polytherimide (Ultem®) 
shell. The bottom of the copper rod inside the sample holder was placed on a 21 mm 
thick polycarbonate plate as the grounded base electrode [108, 117]. 
 
 
 
Figure 4-3. Schematic of the experimental setup for the DBD treatment of blood 
plasma 
 
 
Human whole blood of 150 mL with 1.5 mL of ethylene diaminetetraacetic 
acid (EDTA) as an anti-coagulant was obtained from Lampire Biological 
Laboratories (Pipersville, PA) in a glass bottle. Both the WBV and hematocrit for the 
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blood sample were measured to determine the baseline data prior to the DBD 
treatment. The whole blood in the 150 mL of bottle was then transferred to several 10 
mL-polyethylene tubes to prepare blood plasma from whole blood using a centrifuge 
(VanGuard V6500, Hamilton Bell Co.) with 1,200 G of relative centrifugal force 
(RCF) for 15 min. 
The blood plasma viscosity was measured before DBD treatment for the 
baseline data. Each blood plasma sample separated from whole blood was then 
treated with DBD for 1, 2, 4, and 8 min to investigate the effect of DBD treatment on 
the rheological properties of blood plasma and whole blood. Temperature change was 
monitored before and after the DBD treatment. 
The viscosity of the blood plasma after DBD treatment was measured again 
with viscometers (see below) to compare the change in the plasma viscosity before 
and after DBD treatment. In order to evaluate the change in the WBV due to the 
coagulated particles generated by DBD treatment, some of the DBD-treated blood 
plasma samples were mixed back with the original erythrocytes which had been 
separated in the previous step, and the WBV was measured. For the last step, to 
investigate whether or not the WBV could be reduced by the filtration of the 
coagulated particles from the DBD-treated blood plasma, some of the DBD-treated 
blood plasma samples was filtered using a syringe filter (25 mm, pore size 0.20 μm, 
Nylon, Millipore) and then mixed back with the centrifuged erythrocytes, and the 
viscosities of the mixed whole blood samples were measured.  
Here, hematocrit concentration was also measured to examine any possible 
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plasma loss or hemolysis during the transfer of blood, the centrifugation of blood 
cells, the DBD treatment, the filtration process of DBD-treated blood plasma, and the 
remixing of the DBD-treated blood plasma with the centrifuged erythrocytes. 
WBV was measured at 37oC using the SCTV over a range of shear rates 
from 1 to 1,000 s-1. Detailed test and viscosity calculation procedures are given 
elsewhere [41]. The viscosity of the DBD-treated blood plasma was also measured 
using Brookfield viscometer (LV-III with CP-42, Brookfield Engineering Lab.) at two 
different shear rates of 225 and 450 s-1. The temperature of the test sample at 
Brookfield viscometer was maintained at a constant temperature of 37oC with a 
constant temperature water bath and circulator. Since some plasma volume could be 
lost during the DBD treatment and filtration, the WBV was normalized to a standard 
hematocrit of 45% using a standard hematocrit-correction method [45].  
The mean and standard deviations for both whole blood and blood plasma 
viscosities were calculated. WBV was reported both at the observed (native) 
hematocrit and normalized hematocrit of 45% [45]. 
 
4.2.2 Results and Discussion 
Prior to DBD treatment, the WBV profiles of control blood samples were 
measured using the SCTV and viscosity values at five different shear rates of 1,000, 
300, 100, 10, 1 s-1 were obtained for numerical comparison after DBD treatment. All 
the obtained WBVs including the baseline mean and standard deviation values were 
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normalized to standardized hematocrit of 45%. The normalized WBV of untreated 
blood varied from 35.38 to 301.01 mP when shear rate decreased from 1,000 to 1 s-1. 
 
Table 4-1. The Change of whole blood viscosity after DBD treatment (1 cP = 10 mP) 
DBD 
Treatment 
time 
Shear rate 
(Uncorrected) 
Whole blood viscosity 
(Means ± SD) (mP) 
(Normalized) 
Whole blood viscosity 
(Means ± SD) (mP) 
No treatment 
1,000 s-1 34.65 ± 1.63 35.38 ± 3.28 
300 s-1 38.60 ± 3.39 39.29 ± 2.48 
100 s-1 44.85 ± 4.74 45.68 ± 2.82 
10 s-1 83.85 ± 11.95 86.08 ± 8.13 
1 s-1 286.90 ± 53.60 301.02 ± 56.17 
DBD treated 
(1 min.) 
1,000 s-1 33.79 ± 3.38 38.99 ± 0.82 
300 s-1 37.25 ± 3.87 41.92 ± 0.83 
100 s-1 43.21 ± 6.25 47.89 ± 0.59 
10 s-1 82.94 ± 11.51 93.23 ± 5.10 
1 s-1 291.25 ± 49.75 326.12 ± 44.05 
DBD treated 
(2 min.) 
1,000 s-1 43.73 ± 7.45 41.47 ± 5.06 
300 s-1 46.35 ± 7.41 43.87 ± 4.71 
100 s-1 52.63 ± 6.56 49.66 ± 3.11 
10 s-1 101.28 ± 12.95 93.56 ± 4.08 
1 s-1 370.35 ± 62.98 327.75 ± 27.74 
DBD treated 
(4 min.) 
1,000 s-1 39.50 ± 7.91 38.28 ± 4.48 
300 s-1 43.50 ± 7.77 42.19 ± 3.90 
100 s-1 50.27 ± 7.86 48.75 ± 3.04 
10 s-1 99.33 ± 17.95 95.28 ± 6.14 
1 s-1 353.97 ± 64.75 336.47 ± 45.00 
DBD treated 
(8 min.) 
1,000 s-1 46.27 ± 9.26 44.50 ± 3.79 
300 s-1 49.30 ± 9.92 47.36 ± 3.79 
100 s-1 55.23 ± 9.54 53.23 ± 2.01 
10 s-1 104.90 ± 15.66 101.01 ± 5.86 
1 s-1 383.83 ± 60.19 368.10 ± 65.41 
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When blood plasma was treated with DBD, a white layer formation was 
found on the top surface of the treated blood plasma samples and at the interfacing 
edge with a copper surface, whereas the blood plasma without DBD treatment did not 
exhibit any white particle formation on the sample surface after being exposed to 
open atmosphere for the same duration (see Fig. 4-4). The viscosity of blood plasma 
treated with DBD measured with Brookfield viscometer at two different shear rates, 
225 and 450 s-1 is shown in Fig. 4-5. The viscosity of blood plasma showed irregular 
values in accordance with the DBD treatment time for both shear rates.  
 
 
 
(a) 
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(b) 
 
(c) 
Figure 4-4. Photographs of the formation of white layer in blood plasma sample with 
DBD treatment: (a) blood plasma before DBD treatment showed no coagulation, (b) 
blood plasma treated with DBD for 4 min. exhibited a partially coagulated layer, and 
(c) blood plasma treated with DBD for 8 min. Showed white clotted layer on the 
surface of copper surface 
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Figure 4-5. Variations in the viscosity of blood plasma at two different shear rates, 
225 and 450 s-1 at four different DBD treatment times together with baseline data 
 
 
The values of WBV for the blood samples mixed with blood plasma treated 
by DBD are given in Fig. 4-6 at five different shear rates at each treatment time (i.e., 
1, 2, 4, and 8 min). Over the range of shear rates, the normalized WBV increased with 
increasing DBD treatment time. WBV measured at a high shear rate of 300 s-1 is 
usually termed as systolic whole blood viscosity (SBV), whereas WBV measured at a 
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low shear rate of 1 s-1 is termed as diastolic whole blood viscosity (DBV) as WBV 
varies during a cardiac cycle like blood pressure. As shown in Fig. 4-6, DBV values 
were significantly higher in DBD-treated samples (i.e. 368.10 ± 65.41 mP for 8-min 
DBD treatment case) than untreated control samples (301.02 ± 56.17 mP). SBV 
values were also elevated from 38.60 ± 3.39 mP for control to 49.30 ± 9.92 mP (for 8-
min DBD treatment case).  
 
 
Figure 4-6. Variations in the viscosity of whole blood at four different DBD treatment 
times together with baseline data 
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WBVs of blood samples remixed with DBD-treated blood plasma, which 
was filtered before being mixed with the original red blood cells are shown in Figs. 4-
7 and 4-8. For SBV values shown in Fig. 4-7, the systolic blood viscosity after 8-min 
DBD treatment without filtration increased by 5.5% from the baseline value of 41.0 
mP. When the DBD-treated plasma was filtered and then remixed with red blood cells, 
the systolic blood viscosity decreased by 9.1% from the baseline SBV of 41.0 mP. 
The diastolic blood viscosity of blood treated by DBD but without filtration was 
elevated with increasing DBD treatment time.  For example, the DBV of blood 
increased by 29.9% from the baseline value of 340.7 mP (see Fig. 4-8). When the 
DBD-treated plasma was filtered then remixed with red blood cells, the DBV of 
blood for 8-min treatment case decreased by 17.7% from the baseline value of 340.7 
mP.  
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Figure 4-7. Variations in the systolic blood viscosity of whole blood after DBD 
treatment with and without filtration 
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Figure 4-8. Variations in the diastolic blood viscosity of whole blood after DBD 
treatment with and without filtration 
 
 
When blood plasma was treated by DBD, a white clot layer was formed at 
the top of blood plasma sample (see Fig. 4-4), suggesting that the plasma proteins and 
lipids in blood plasma might have precipitated into coagulated particles through DBD 
treatment. Accordingly, if these coagulated particles are removed, one may anticipate 
some improvement in the rheological properties of whole blood.  Note that the size 
of fibrinogen (diameter of 5-7 nm and length of 48 nm) and LDL molecules 
(approximately 22 nm) are too small to be removed by filter [118-120]. 
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Although DBD discharge employed in this study is non-thermal, there could 
be about 20 % of thermal energy to be transferred from filamentary discharge to the 
blood plasma sample due to energy distribution of input power to the metallic 
electrode [121, 122], a phenomenon which could create the white layer of coagulated 
particles by heating effect. To test this possibility, temperature measurement was 
performed before and after the treatment of the samples with DBD, and no significant 
change in temperature was observed, suggesting that the coagulated particles must 
have come from the oxidation and subsequent coagulation by active species 
generated by DBD.  In addition, there was no change in hematocrit between before 
and after DBD treatment, indicating no significant evaporation in blood plasma 
during the DBD treatment procedure. 
Two important buffer systems exist in blood plasma, dihydrogen phosphate 
buffer and carbonic acid buffer. The dihydrogen phosphate buffer resists a drop in pH, 
while the carbonic acid buffer resists a rise in pH [123]. It has been known that when 
non-thermal plasma discharge is applied to liquids, it generates a significant amount 
of hydrogen ions, which change the acidity of liquids. The effect of DBD discharge 
on phosphate buffered liquids which is similar to the buffering system of blood 
plasma has been investigated and confirmed that when about 5-mL phosphate 
buffered solution was treated with DBD discharge, the phosphate buffer system 
prevented the acidification of the liquids, while treating smaller volume (i.e. less than 
about 1.5 mL) for longer than about 10 min. could be susceptible to the acidification 
of DBD discharge [112, 124]. In the present study, the 4-mL blood plasma sample 
was treated with DBD discharge for maximum 8 min., thus we assumed that the 
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acidification of 4-mL blood plasma sample could not be significantly affected by 
DBD plasma discharge.   
The blood mixed with the blood plasma treated by DBD without filtration 
showed significant increase in WBV. This can be attributed to the fact that plasma 
proteins and lipids formed large groups of coagulated particles of micron size, 
increasing frictional resistance to flow over the entire range of shear rates. Since the 
coagulated particles are visible (i.e., large in size), they could be relatively easily 
removed with filtration, a process which helped reducing WBV as the plasma 
proteins and lipids are the key determinants of WBV. 
The SBV of blood with DBD treatment and filtration decreased by about 9.1% 
from the baseline value, whereas the DBV dropped by 17.7% from the respective 
baseline values, both representing significant improvements in rheological properties. 
The reason why the DBD treatment improved the DBV more than the SBV is as 
follows: The SBV is usually affected by erythrocyte deformability while DBV is 
affected by the erythrocyte aggregation. Since the plasma proteins (i.e., fibrinogen 
and immunoglobulin) and LDL molecules are instrumental in the RBC aggregation 
[13, 94], their removal by the DBD treatment and filtration should mitigate the 
erythrocyte aggregation, subsequently reducing the DBV.   
In terms of the mechanism of DBD treatment in the precipitation of plasma 
proteins and lipids from blood plasma, Kalghatgi et al. [108] reported that DBD 
treatment might have activated some of protein coagulation process which resulted in 
rapid fibrinogen aggregation. It was also mentioned that the selective coagulation of 
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proteins was observed – not of albumin but of fibrinogen only [108]. We can 
hypothesize that this coagulated fibrinogen and subsequent removal might have 
affected the WBV of blood with DBD-treated blood plasma. 
In addition, oxidized LDL molecules are known adhere to arterial wall 
surfaces, playing a key role in the progression of atherosclerosis [125, 126]. In a 
similar manner, from the reduction of DBV, we can indirectly hypothesize that LDL 
molecules in blood plasma might have been oxidized by DBD treatment, and the 
oxidized LDL molecules may tend to precipitate and coagulate, a phenomenon which 
requires further investigation. Since LDL molecules are one of the important 
variables in WBV [127-129], their removal with DBD treatment and filtration should 
not only help reducing WBV [130] but also reducing the progression of 
atherosclerosis. 
 
4.3 The Effect of Corona Discharge Treatment on Blood Viscosity 
4.3.1 Methods 
An experimental setup was prepared to generate a pulsed corona discharge 
as shown in Figs. 4-9 and 4-10. This system was originally constructed with three 
components (i.e. a high-voltage dc power supply, a spark-gap switch, and a point-to-
plain electrode) and could be utilized to generate a pulsed corona, arc or spark 
discharge with capacitors according to its application. When the spark-gap switch 
was triggered, the capacitor bank (8.5nF) charged by a pulsed power supply could 
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A corona discharge could be generated when the ionized region (or the 
potential gradient of electric field) around an electrode became high enough to grow, 
but limited to a certain radius. Thus, streamer filaments did not propagate across the 
electrode gap. If the potential gradient became too high, it could generate electrical 
breakdown and form an arc or spark discharge. One prepared a point-to-plane 
geometry of electrodes and immersed in a 10-mL cylindrical container filled with 
blood plasma. A tungsten needle electrode (3 mm in outer diameter and 150 mm in 
length) was prepared as an anode and completely insulated from surrounding blood 
plasma except for the 2-mm tip of the needle.  
In order to generate a pulsed corona discharge and avoid electrical 
breakdown, the gap between the electrodes was maintained to be 30 mm, and the tip 
of the tungsten needle electrode was mechanically grounded to 0.5 mm in the radius 
of curvature at the tip of the anode. The electric field on the needle tip could be 
estimated by the following equation: 
E~U/rୡ                          (Eq. 4-1) 
where U and rୡ are the applied voltage and radius of curvature of the needle, 
respectively [132, 133]. By maintaining the gap between the electrodes and the radius 
of curvature of the needle tip relatively large, a pulsed corona discharge could be 
generated without breakdown. 
In order to prepare blood samples, 200 mL of normal whole blood was 
obtained from a volunteer and collected in a glass container, which had contained 2 
mL of ethylene diaminetetraacetic acid (EDTA) as an anti-coagulant. 
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The whole blood sample in a glass container was gently and homogeneously 
mixed. Then, it was transferred to 10-mL polyethylene transparent tubes for the 
separation of cells from whole blood by centrifuge so that one could obtain blood 
plasma. After completion of centrifuge (VanGuard V6500, Hamilton Bell Co.) for 15 
min with a relative centrifugal force (RCF) of 1,200 G, the separated blood plasma 
from whole blood was transferred to another empty 10-mL transparent container for 
corona discharge treatment. 
Same as the previous DBD experiment, WBV was measured at 37oC using 
the SCTV over a range of shear rates from 1 to 1,000 s-1. Detailed test and viscosity 
calculation procedures are given elsewhere [41]. 
The experimental procedure for corona discharge treatment to blood plasma 
was shown in Fig. 4-11. The WBV profile over a range of shear rates from 1 to 1,000 
s-1 was measured in order to determine the baseline values before the blood samples 
were centrifuged. Hematocrit was also measured to confirm that no hemolysis took 
place while the blood cells were centrifuged, transferred, and mixed back with blood 
plasma. 
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the change of plasma viscosity before and after the corona discharge treatment. Then, 
the corona-treated blood sample was filtered using a syringe filter (25mm, pore size 
0.20 μm, Nylon, Millipore) to investigate whether or not the coagulated particles 
could be removed by filtration. The blood plasma samples treated with a pulsed 
corona discharge and then filtered were mixed back with red blood cells to measure 
the profiles of WBV. 
The change of LDL concentration in whole blood between before and after 
filtration was monitored using an LDL measuring equipment (Cardio Check Monitor 
and LDL Direct Cholesterol Test Strips, POLYMER Technology systems) to check if 
LDL was removed by the coagulation using a pulsed corona discharge and 
subsequent filtration. 
The mean and standard deviations for whole blood viscosity, blood plasma 
viscosity, and LDL values were calculated. WBV was reported at the normalized 
hematocrit of 45% for comparison [45]. 
 
4.3.2. Results and Discussion 
Figure 4-12 shows the profiles of WBV after a pulsed corona discharge 
treatment. Once blood plasma samples were separated from whole blood, they were 
treated with a pulsed corona discharge. Then, they were mixed back with the 
separated blood cells to investigate the effect of corona discharge on WBV. As seen in 
Figs. 4-12 and 4-13, WBV at low shear rate ranges showed a large increase as the 
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treatment time of a pulsed corona discharge increased. For example, DBV (at a shear 
rate of 1 s-1) increased by 42.6% from 297.69 mP to 424.53 mP after corona discharge 
treatment for 90 pulses. 
 
 
 
Figure 4-12. Profiles of WBV over a shear rate range from 1 to 1,000 s-1 after blood 
plasma treated by corona discharge was mixed back with blood cells 
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Figure 4-13. Comparison of WBVs at shear rates of 1, 10, 100, 300, and 1,000 s-1 
blood plasma treated by corona discharge was mixed back with blood cells 
 
 
Figure 4-14 shows the profiles of WBV over high shear rate ranges from 100 
to 1,000 s-1 after corona-treated blood plasma was mixed back with blood cells. As 
shown in Fig. 4-13, the WBV at high shear rate ranges also increased as the blood 
plasma sample was treated for longer pulses, i.e. 15, 30, 60, and 90 pulses of corona 
discharge. However, the increased amounts of WBV at high shear rate ranges were 
smaller than those at low shear rate ranges. For example, the SBV (at a shear rate of 
300 s-1) showed an increase by 17.2 % from 40.53 mP to 47.50 mP after the blood 
plasma was treated for 90 pulses with corona discharge, whereas the DBV (at a shear 
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rate of 1 s-1) increased by 42.6 %, 2.5 times higher than the SBV. This indicated that a 
pulsed corona discharge could affect greater to the WBV at low shear rate ranges than 
that at high shear ranges, a finding which was similar to the results of DBD discharge 
to blood plasma in the previous experiment. 
The fluidity of blood depends not only on the volumetric fraction of blood 
cells (i.e. hematocrit), but also on the behavior of those cells under shear forces (i.e. 
deformability, orientation, and aggregation of red blood cells).  
 
 
 
Figure 4-14. Profiles of WBVs over high shear rate ranges from 100 to 1,000 s-1 after 
blood plasma treated by corona discharge was mixed back with blood cells 
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At low shear rates, several studies have indicated that the erythrocyte tends 
to aggregate into linear arrays and form three-dimensional structures like stacks of 
coins, a phenomenon which is known as Rouleaux formation [134]. Because of the 
increased effective particle size by the erythrocyte aggregation, the disturbance of 
flow streamlines becomes more pronounced, and accordingly blood viscosity is 
significantly increased at the low shear rates. Thus RBC aggregation becomes a 
major determinant of blood viscosity under low shear conditions [135].  
The aggregation has been known to be strongly affected by the concentration 
of macromolecules such as fibrinogen and low density lipoprotein (LDL) cholesterol 
molecules in blood plasma [18, 128, 134, 136, 137]. According to Bridging model 
theory, one of the widely accepted models explaining the mechanisms of RBC 
aggregation, the RBC aggregation occurs when a bridging macromolecule with a 
diameter greater than 19 nm binds to two erythrocytes, such that the distance between 
two erythrocytes is maintained to be about 19 nm [127, 137-140].  
In case of fibrinogen, a long chain molecule with a length of approximately 
47-48 nm, it adheres to the membrane surface of erythrocytes [141] and establishes a 
cross-linking network structure when RBCs are near at low shear conditions. For 
LDL cholesterol molecules, since the diameter of LDL cholesterol molecules is about 
18-30 nm, they can easily bind to two adjacent erythrocytes, and form the RBC 
aggregation, and thus increase blood viscosity at low shear rates [137, 138] 
Therefore, the phenomena that the WBV at low shear rates had been 
increased significantly after blood plasma was treated with pulsed corona discharge 
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might be explained follows: when the macromolecules are treated with a pulsed 
corona discharge, the discharge enhances the coagulation of macromolecules, and 
thus the size of macromolecules increases greater than their original size. Then, the 
coagulated macromolecules might bind to the erythrocyte membrane, enhancing the 
formation of aggregation, and thus increasing WBV particularly at low shear rates.  
At high shear rates, it has been known that RBC deformation is the primary 
factor affecting WBV [135, 142] as the increased shear force disaggregates the 
Rouleaux formation. RBCs, highly specialized cells, respond to the applied forces by 
extensive change of their shape, with the degree of deformation under a given force, 
which is known as deformability. These cells behave as elastic bodies and their shape 
is reversible when the deforming forces are removed [135, 143]. Cytoskeleton which 
is a network of proteins lying just beneath the cell membrane is accepted as a major 
contribution to the rigidity of RBC membrane, thus the maintenance of normal 
mechanical behavior of RBC depends on a low cytosolic calcium level adjusted by an 
active ATP-dependent calcium pump under RBC membrane [135, 144]. LDL 
cholesterol also can decrease the erythrocyte deformability by increasing the 
cholesterol-to-phospholipid ratio at the erythrocyte membrane [127, 137] even though 
its contribution to deformability is less than that to aggregation. In addition, glucose, 
osmolality, and dehydration adversely affect the rigidity of erythrocyte membrane 
[137].  
Considering the determinants of the erythrocyte deformability mentioned 
above, the reason of WBV increase at high shear rate ranges, as seen in Figs. 4-13 
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and 4-14, could be suggested as follows: the coagulated LDL by corona discharge 
treatment might play a significant role in the increase of WBV at higher shear rates 
by promoting the rigidity of erythrocytes as mentioned above. Another possibility 
may be suggested that the increased size of macromolecules could attribute to the 
increase of plasma viscosity as the concentration of macromolecules in suspension 
medium increases, thus causing an overall increase of WBV profiles over all shear 
rate ranges. 
Thus, the present study hypothesized that the coagulated macromolecules by 
corona treatment, such as fibrinogen and LDL cholesterol, might have affected both 
the erythrocyte aggregation at low shear rates and the erythrocyte deformation at high 
shear rates, both of which might have attributed to the increase of plasma viscosity 
and resulted in the increase of WBV at overall shear rates. In order to verify the 
hypothesis, the blood plasma treated with the corona discharge was filtered using a 
syringe filter, and then mixed back with RBCs. 
Here, a syringe filter with 200 nm in pore size was used to investigate the 
effect of the corona discharge on the size growth of macromolecules, of which the 
normal size is 47-48 nm for fibrinogen and 18-30 nm for LDL cholesterol. 
Figure 4-15 shows the profiles of WBV over a shear rate range from 1 to 
1,000 s-1 after blood plasma was treated with the corona discharge and filtered, then 
mixed back with blood cells. The profiles of WBV showed an overall drop after 
filtration, representing the improvements in hemorheological properties. As clearly 
seen in Fig. 4-16, the longer time the blood plasma was treated with the corona 
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discharge, the greater reduction of WBV was achieved after the filtration. However, 
the decrease in WBV was mostly observed at low shear rate ranges, for example, 
DBV (at shear rate 1 s-1) dropped by about 30.1% (from 297.69 mP to 207.96 mP) 
from the baseline value, whereas the SBV (at 300 s-1) showed no significant change 
in blood viscosity from baseline value. As shown in Fig. 4-17, at high shear rate 
ranges (i.e. from 100 to 1,000 s-1), no increase or decrease in WBV profiles was 
observed.  
Note that the blood plasma sample treated with 90-pulse corona discharge 
was not able to be completely filtered using a 200 nm-syringe filer since the 
coagulated particles were so large to clog the filter membrane after about 3 mL out of 
10 mL-blood plasma volume had been filtered.  
 
 
Figure 4-15. Profiles of WBV over a shear rate range from 1 to 1,000 s-1 after blood 
plasma was treated with corona discharge, filtered, and then mixed back with blood 
cells 
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Figure 4-16. Change of WBVs for shear rates of 1, 10, 100, 300, and 1,000 s-1 after 
blood plasma was treated with corona discharge, filtered, and then mixed back with 
blood cells 
 
 
Figure 4-17. Profiles of WBVs over a high shear rate range from 100 to 1,000 s-1 after 
blood plasma was treated with corona discharge, filtered, and then mixed back with 
blood cells 
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Figure 4-18. Change of LDL after filtration for 15-, 30-, and 60-pulse corona treated 
blood plasma 
 
The change of LDL was also monitored during the experiment, and Fig. 4-18 
shows the reduction of LDL after filtration.  
After the concentration of LDL was initially measured before the centrifuge 
of whole blood, the centrifuged blood plasma was treated with the corona discharge 
for different pulses, then filtered using a syringe filter. The filtered blood plasma was 
mixed back with blood cells, and then LDL was measured again to investigate the 
effect of both corona treatment and filtration on the removal of LDL in blood.  
The rate of LDL reduction became larger as the treatment time increased, 
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which made possible to indirectly assume that the longer blood plasma was treated 
with the corona discharge, the more oxidized LDL molecules greater than 200 nm in 
diameter existed, large enough to be filtered. For example, LDL in the corona-treated 
blood plasma for 60 pulses dropped by 31.5% from 132.79 to 90.00 mg/dL. 
The graphs showing the effect of filtration on the change of WBV (i.e. DBV 
and SBV) are shown for comparison in Figs. 4-19 and 4-20, respectively. For DBV 
case, the linearly increased DBV with an increase of corona treatment time had a 
significant drop after filtration. This reduction became bigger as it was treated with a 
longer time. However, for SBV case, even though SBV increased as it was treated 
with the corona discharge, it showed almost no change in SBV after filtration. 
 
Figure 4-19. Changes of DBV at shear rate 1 s-1: a) blood plasma was treated with 
corona discharge, then mixed back with blood cells, and b) blood plasma was treated 
with corona discharge, filtered, and then mixed back with blood cells 
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Figure 4-20. Changes of SBV at shear rate 300 s-1: a) blood plasma was treated with 
corona discharge, then mixed back with blood cells, and b) blood plasma was treated 
with corona discharge, filtered, and then mixed back with blood cells 
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(i.e. oxidized LDL) using a filter, one could achieve a significant reduction of DBV 
compared to the baseline value. In other words, as the coagulated LDL molecules 
were removed, the erythrocyte aggregation was reduced accordingly, thus decreased 
the frictional resistance of blood flow in small vessels at low shear rates. 
For SBV at high shear rate, one could hypothesize that the coagulated LDL 
molecules could affect to the erythrocyte rigidity, increasing blood viscosity at high 
shear rates. If the erythrocyte deformability thus had been affected by the coagulated 
LDL molecules, SBV should have decreased at least lower than the baseline value as 
the coagulated LDL had been removed by a filter. However, as shown in Fig. 4-20, 
even though the coagulated LDL was reduced, no significant difference was observed 
in SBV compared to the baseline value, a finding which explained that the above 
hypothesis was not appropriate for the SBV at the high shear rates. 
Instead, the increase of WBV at low shear rates could be explained as 
follows: the coagulated macromolecules (i.e. fibrinogen and LDL) might enhance the 
level of plasma viscosity as the concentration of the macromolecules increases after 
the corona treatment. Such an increase of plasma viscosity could affect the overall 
fluidity of whole blood shown in Fig. 4-20 that the increased SBV after the corona 
treatment had returned to the baseline value after the removal of the coagulated LDL 
molecules by filtration. 
In order to verify that the coagulated macromolecules could promote an 
increase of plasma viscosity, thus enhancing an overall increase of WBV, blood 
plasma samples were prepared and treated with the corona discharge for 90 pulses. 
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Plasma viscosity was measured after the corona discharge treatment was completed 
as well as after filtration process was completed using a syringe filter. However, 
instead of using a 200-nm syringe filter used in the previous experiment, a 3-μm 
syringe filter larger in pore size was used to avoid the clogging of a filter during 
filtration. 
 
 
 
Figure 4-21. Changes of plasma viscosity for 3 cases; control, after corona discharge 
treatment but before filtration, after corona discharge and filtration 
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reduction in blood plasma viscosity by -25.8% from the baseline value. 
Generally, the viscosity of blood plasma, a highly concentrated protein 
solution, is determined by water-content and macromolecular components [55]. The 
level of blood plasma viscosity increases when the protein in blood plasma has less 
spheroid shape, higher molecular weight, and higher concentration [55]. Thus the 
increase of blood plasma viscosity after the corona treatment might have been 
promoted by the same reasons, i.e., enhanced by the coagulation of macromolecules 
in blood plasma with the corona treatment. 
Blood plasma is considered as a Newtonian fluid, where viscosity is 
independent on shear rates. Such Newtonian characteristics of blood plasma can be 
observed in Fig. 4-21, showing a nearly constant viscosity over shear rates from 10 s-1 
to 1,000 s-1. 
However, for shear rates below 10 s-1, the plasma viscosity showed non-
linear behavior, rather close to the characteristics of non-Newtonian fluidity. Any 
fluids with suspended particles could have the yield stress. The yield stress in the 
blood plasma can be determined as the minimum limit of shear stress to initiate the 
flow of fluids [3]. It is caused by the interactive forces between suspended particles in 
fluid. Thus, blood plasma, a highly concentrated protein solution, might also have a 
yield stress due to weak but still abundant protein-to-protein interacting forces [55]. 
Since the interaction between proteins in blood plasma is weaker compared to the 
erythrocyte aggregation in whole blood, the yield stress of blood plasma can be 
relatively easily broken and overcome even by a small increase of shear force, in 
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other words, by a small increase of shear rates (i.e. over 10 s-1 in Fig. 4-21). Once the 
yield stress of blood plasma is broken, it would behave as a Newtonian fluid, 
showing a constant viscosity. As shown in Fig. 4-21, as the coagulated proteins by the 
corona discharge treatment were removed after filtration, the non-Newtonian 
behavior of blood plasma has clearly disappeared, showing a constant viscosity down 
to a shear rate of 5 s-1. 
The present study experimentally investigated the effect of corona discharge 
on the coagulation of LDL. The effect of non-thermal plasma discharge on the 
coagulation of fibrinogen was investigated by other researchers [108]. The plasma-
treated fibrinogen exhibited a multimodal distribution of sizes, with the largest 
increase in size by about two orders of magnitude as compared to the control [108]. 
Thus, one can postulate that the coagulated fibrinogen and subsequent removal could 
also affect the similar improvement in WBV as the coagulated LDL did.   
Thus, we can conclude, as in the DBD experiment, that both LDL and 
fibrinogen molecules in blood plasma might have been oxidized by the corona 
discharge treatment, and the oxidized macromolecules may tend to precipitate into 
relatively large size particles and can be removed by filtration. This requires further 
investigation in the coagulation mechanism of LDL and fibrinogen. 
 
4.4 Limitations 
The present study clearly demonstrated that treatments with electrical plasma 
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discharges (i.e., both DBD and corona discharges) followed by filtration of the 
coagulated particles could reduce WBV. The results indicated that the non-thermal 
DBD treatment might have precipitated and coagulated plasma proteins (i.e., 
fibrinogen) and LDL molecules in blood plasma, contributing the feasibility of the 
use of electrical plasma technology to improve blood viscosity. However, the 
potential application still remains theoretical, and several issues still need to be 
further investigated before the implementation of this technology in vivo. 
Thus, a comprehensive study should be performed to investigate 1) the 
mechanism of the coagulation of proteins and LDL molecules, 2) the biological 
effects of active species generated by electrical plasma discharge on blood 
properties, 3) the change of the functional properties of blood plasma after 
electrical plasma treatment, and 4) the issue of preservation of vital biological 
properties of blood plasma. Since very few papers have been published about the 
effect of electrical plasma on blood, it would be an interesting subject for the 
future study more oriented toward biomedical field.  
In addition, the catalytic effect of tungsten electrode material on blood 
properties also needs to be investigated for a potential application of corona discharge. 
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CHAPTER 5: A STANDARD VISCOSITY FLUID FOR BLOOD VISCOSITY 
MEASUREMENTS 
5.1 Motivations and Literature Survey on a Standard Viscosity Fluid for Blood 
Viscosity Measurements 
As previously explained in Fig. 1-2 of Chapter 1, one of the most important 
experimental principles of the SCTV system is that the height difference of fluids 
moving in two vertical riser tubes is measured using optical detectors, where CCDs 
are able to detect the rate of the height change as the light emitted from LEDs is 
blocked by blood in the riser tubes [43].  
Even though this system does not require a calibration since the height 
difference is naturally driven not by any external mechanical forces but by the 
gravitational force, a standard viscosity fluid (SVF) for the present SCTV system is 
essential in order to validate its functionality and reliability in operation.  
In addition, it is also needed to propose a SVF due to the limitation of using 
human blood in hemorheological experiments, such as to experimentally investigate 
the flow characteristics of blood in a stenosis or bifurcation of vessel models or to 
verify the result of a numerical simulation through in vitro experiments, etc. 
A brief summary for the requirements of the SVF to be proposed is as follows: 
1) It should to be opaque so that CCD-LED light sensors can detect the 
height difference of fluid. 
2) It should properly behave as a shear-thinning non-Newtonian fluid which 
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changes its viscosity according to different shear rates.  
3) The viscosity levels of the SVF should be controllable and reproducible 
when prepared with the same formula.  
4) It should maintain its viscosity stable for a certain period, in other words, 
the degradation of the SVF should not take place over time. 
 
As discussed previously, the reason why the blood behaves as a shear-
thinning non-Newtonian fluid is due to (1) the aggregation of red blood cells as a 
result of complicated intermolecular interactions between macro-molecules and red 
blood cells when shear rate is low and (2) the dispersion of the aggregated red blood 
cells as the shear rate increases [1-3, 14, 145]. Thus, the blood behaves as a non-
Newtonian fluid where its viscosity exhibits shear-thinning characteristics with the 
change of shear rates, and a proper SVF might have to replicate such characteristics 
of blood flow [146]. 
Reviewing previous studies related to SVF, the closest candidate was the 
development of blood analog fluid. Blood analog fluid is defined as a compound 
having a structure similar to that of blood, but differing from blood in respect of 
certain components, such as physical, chemical, or biochemical properties (cited from 
Wikipedia). The methods of constituting a blood analog fluid have been carried out in 
several previous studies [145-157], mainly, with water-soluble polymer-based 
materials. The purpose of using high molecular weight polymer-based materials was 
to simulate the complicated intermolecular interactions of macro-molecules existing 
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in blood plasma since the water-soluble polymer-based materials contain long chain 
structures. Hence, they are expected to behave as those of macro-molecules in blood 
even though the chemical compositions between macro-molecules and water-soluble 
polymer-based materials are quite different from each other. 
Brookshier et al. first suggested aqueous solutions of Xanthan gum and 
glycerin as blood analog fluid and compared their flow behavior to that of blood in 
straight and athergenic-curved artery models by measuring the wall shear rate in a 
pulsatile flow, suggesting its applicability in replicating the behavior of a non-
Newtonian fluid [147].  
Thurston investigated the viscoelastic properties of an aqueous polymer 
solution and developed a rheological model based upon a multiple relaxation process 
from a generalized Maxwell model [156, 157]. 
Gijsen et al. utilized an aqueous Xanthan gum solution to give shear thinning 
and viscoelastic behavior at a Newtonian control fluid, which was a concentrated 
solution of Potassium Thiocyanate in water (KSCN, 71 wt%) with a viscosity of 2.9 x 
103 Pa.s, and a density of 1410 kg/m3. The effect of the non-Newtonian 
characteristics on the flow in a carotid bifurcation was studied using optical flow 
visualization methods. The non-Newtonian behavior between blood and the Xanthan 
gum solution with KSCN resulted in a good agreement with both shear-thinning and 
oscillatory-viscous behavior while different in oscillatory-elastic behavior [146]. 
Nguyen et al. performed the analysis of experimental flow visualization in 
hydraulic cardiovascular models using Diethyl Phthalate (Purum 99%, Sigma Aldrich) 
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with Ethanol as blood analog fluid, representing acceptable compatibility with 
polymethyl methacrylate (PMMA n=1.491). Interestingly, a procedure of selecting 
blood analog fluid from several initial fluid candidates referred from Handbooks and 
Material Safety Datasheets (MSDS) was described in detail in the study, considering 
the conditions required for flow visualization model [152]. 
With recent advances in MEMS technology, several studies [149, 154, 155] 
related to the blood flow in a micro-scale channel have recently been performed using 
blood analog fluid. Sousa et al. [154] investigated the extensional flow of blood 
analog solutions, using a polyacrylamide (125 ppm weight/weight) and Xanthan gum 
(500 ppm weight/weight), through microfluidic channels composed of hyperbolic and 
sudden contradiction or expansions. The flow pattern of the two blood analog 
solutions were investigated considering both the shear-thinning behavior and elastic 
characteristics of the fluids at microscale [154].  
In a similar manner, Sribastava et al. [155] used polyethylene oxide (PEO), 
hydrolyzed polyacrylamide (PAM), and Xamthan gum to examine the characteristics 
of non-Newtonian fluid in micro-channels [155]. In addition, Hu et al. [149] utilized 
an aqueous Xanthan gum solution as blood analog fluid to study the effect of 
viscoelastic fluid on the performance of an axial blood pump model [149]. 
Thus, polymer-based aqueous blood analog fluids have showed a wide 
applicability to various experiments related to the flow of blood. Their inexpensive 
cost and easiness in adjusting the viscosity by simply changing the concentration of 
the compounds were also contributed to their popularity. 
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Although they properly behaved as a shear-thinning non-Newtonian fluid 
with the change of blood viscosity over a range of shear rates, no researches have 
been performed on an opaque blood analog fluid since most of the studies were 
conducted using a conventional rotating or capillary tube viscometer. Some studies 
have employed optical techniques to visualize the flow characteristics of blood 
analog fluids. However, transparent and laser-induced fluorescent substances were 
utilized in those studies [146, 147]. In addition, the polymer-based aqueous blood 
analog fluid could be degraded after circulation through a pump within 1-2 days due 
to its high molecular weight with long-chain structures (i.e, Mw > 106). Thus, such a 
fluid shows inadequate flow characteristics by losing their shear-thinning non-
Newtonian properties, limiting its applicability. Thus, it does not satisfy the 
requirements of SVF, mentioned above [151, 155]. Lastly, although the 
aforementioned blood analog fluids showed possible applications to the experiments 
related to the non-Newtonian flow, no comprehensive experiments in regards to 
controllability and reproducibility for different viscosity levels have been performed.  
Thus, the objectives of the present study were to propose a new opaque SVF 
to replicate the non-Newtonian behavior of blood for different shear rates, to 
investigate the effect of dye concentration on the viscosity change of the new opaque 
SVF, and to validate the experimental accuracy and repeatability for blood viscosity 
measurement using the SCTV. 
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5.2 Experimental Methods  
5.2.1 Sample Preparation 
In the present study, the maltose with 55% of concentration (i.e., a corn 
syrup: commercial name of maltose) was prepared. It is commercially produced by 
adding the enzymes, such as α-amylase, β-amylase, and pullulanase to a mixture of 
corn starch and water. The advantage of using the maltose with 55 % of concentration 
was that it contained a certain potion of various types of saccharide molecules with 
very low molecular weight, i.e. 55% maltose (a disaccharide formed with double-
linked glucose), oligosaccharide (a saccharide polymer containing the links of 2-10 
monosaccharide), and monosaccharide (glucose), which differed from the polymer-
based aqueous blood analog fluid with high-molecular weight (up to 6 x 106) [155, 
158]. 
Three different levels of SVFs having high, medium, and low viscosity were 
prepared to investigate the effect of the corn syrup concentration on the viscosity of 
the SVFs. In order to prepare SVFs, the syrup and distilled water were mixed in a 
beaker following the mixing formula as given in Table 5-1. The mixture was first 
stirred manually until there was no string-like dense syrup observable in the liquid 
mixture and, then, the beaker with the mixture solution was put on a magnetic stirrer 
(HSD-180, Mtops) for an automated stirring for 10 min. 
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Table 5-1. Mixing formula to prepare three different levels of SVFs having high, 
medium, and low viscosities 
Range of 
viscosity 
Formula 
Concentration of 
syrup 
High viscosity 
Syrup 20.76g 
0.5810 Distilled water 14.97g 
Dye 0.10g 
Medium viscosity 
Syrup 22.00g 
0.4889 Distilled water 23.00g 
Dye 0.10g 
Low viscosity 
Syrup 22.00g 
0.4314 Distilled water 29.00g 
Dye 0.10g 
 
 
The weights of the corn syrup and distilled water were precisely measured 
using a digital scale (CUX-420H, CAS) with a 0.001 g of resolution. Aqueous soluble 
food dye (Black color, McCormick) was added to the mixture of the syrup and 
distilled water to make the SVF opaque. Then, the SVFs were transferred into 4-mL 
plain vacutainers for viscosity measurements using the SCTV. 
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Figure 5-1. Magnetic stirrer and a 4-mL plain vacutainer used to prepare SVFs in the 
present study 
 
 
5.2.2 Experimental Procedures 
In order to investigate the effect of dye concentration on the viscosity of 
SVFs, high, medium, and low standard fluids at three different viscosity levels, 
respectively, were prepared with three different dye concentrations (i.e. 0.05g, 0.10g, 
and 0.15g). The effect of dye concentration less than 2% on the viscosity change of 
an aqueous solution was reported negligible by Kim et al. [43]. Thus, the specific 
purpose of the present study was to determine the minimum threshold of dye 
concentration below which the SCTV system could detect the mixture solution of the 
corn syrup and the dye as an opaque fluid. 
After the completion of dye concentration study, six sets of repeatability test 
for the SVFs were performed using three different viscosity levels of standard fluids, 
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i.e., high, medium, and low viscosity fluids.  
The degradation of the three different levels of opaque SVFs was also 
investigated over 6 months by periodically measuring the viscosity of SVFs. 
In addition, the present study examined the effect of an anti-coagulant (i.e., 
EDTA) used in vacutainers, which is a necessary chemical for the blood of a patient 
to be directly collected and stored prior to WBV measurement. The three different 
viscosity levels of SVFs were stored in two different kinds of vacutainers, 4-mL plain 
vacutainer (no additives) and 4-mL EDTA vacutainer and the viscosity of SVFs were 
measured over 6 months. 
The obtained viscosity data were averaged and the coefficient of variation 
was calculated to quantify the dispersion or scatter of the measured viscosities in 
terms of a normalized distribution. 
 
5.3 Results and Discussion 
5.3.1 Viscosity Profiles of SVFs 
Figure 5-2 shows the results of three different viscosity levels of SVFs (high, 
medium, and low viscosities) together with normal WBV for comparison. All three 
curves obtained from the SVFs showed typical non-Newtonian characteristics both at 
high shear rates and at low shear rates. When compared to the viscosity curve 
produced by normal whole blood, the medium level SVFs showed an excellent 
agreement with the behavior of normal whole blood. 
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Figure 5-2. Viscosity profiles of three different levels of SVFs and normal whole 
blood for comparison according to the change of shear rates 
 
 
Among the three viscosity curves of high, medium, and low SVFs, 
distinguishable differences in viscosity levels were also observed, indicating that the 
control of viscosity levels could be achieved by adjusting the syrup concentration on 
the SVFs (i.e., 0.5810, 0.4889, and 0.4314 of syrup concentration for high, medium, 
and low viscosities, respectively).  
As seen in Table 5-2, the mean systolic viscosities measured at a shear rate 
of 300 s-1 were 74.0 mP for high SVF, 40.2 mP for medium SVF, and 31.5 mP for low 
SVF, respectively. The mean diastolic viscosities measured at a shear rate of 1 s-1 
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were 557.8 mP for high SVF, 218 mP for medium SVF, and 87.9 mP for low SVF, 
respectively. The viscosity values cover the variations found in a clinical range of 
blood viscosities: high (500~600 mP), medium (200~240 mP), and low (80~100 mP)  
ranges.  
 
 
Table 5-2. Results of viscosity measurements from three different SVFs having high, 
medium, and low viscosities (1cP = 10 mP) 
Shear rate  
(1 s-1) 
Viscosity (mP) 
High viscosity Medium viscosity Low viscosity 
1,000 73.1 39.3 30.3 
300  
(Diastolic) 
74.0 40.2 31.5 
150 74.8 42.0 32.7 
100 75.4 44.1 33.5 
50 77.3 49.2 35.4 
10 139.5 73.9 44.2 
5 198.0 95.6 51.4 
2 344.5 147.0 67.4 
1  
(Systolic) 
557.8 218.0 87.9 
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The effect of the syrup concentration on the viscosity change in SVFs is 
shown in Fig. 5-3. These curves could be used to produce any levels of SVFs within a 
range from 200 mP to 600 mP in diastolic viscosity, and from 30 mP to 80 mP in 
systolic viscosity. 
 
 
 
Figure 5-3. Changes of diastolic/and systolic viscosities according to the 
concentration of syrup used in the present study 
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5.3.2 Dye Concentration 
Figure 5-4 shows the viscosity data obtained from high, medium, and low 
SVFs with three different dye concentrations (i.e. 0.05g, 0.10g, and 0.15g). The 
viscosity curves showed that the effect of dye concentration for 0.05g, 0.10g, and 
0.15g on the change of viscosity was negligible as was reported by the previous 
research [43]. In addition, the minimum dye concentration detectable by the SCTV 
system was achieved to be as low as about 0.2 % by weight as listed in Table 5-3. 
 
 
Figure 5-4. Viscosity changes of SVFs according to different dye concentrations 
(0.05g, 0.10g, and 0.15g) 
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Table 5-3. Changes of systolic/diastolic viscosities according to different dye 
concentrations: 0.05g, 0.10g, and 0.15g (1 cP = 10 mP)  
Viscosity 
level 
Formula 
Amount
of dye (g)
Concentration
of dye by 
weight (%) 
Systolic 
viscosity 
(mP) 
Diastolic 
viscosity 
(mP) 
High 
viscosity 
Syrup 20.76g 
Distilled water 14.97g
0.05g 0.140 70.2 551.8 
0.10g 0.279 70.2 575.9 
0.15g 0.418 68.8 570.8 
Medium 
viscosity 
Syrup 22.00g 
Distilled water 23.00g
0.05g 0.111 40.5 231.5 
0.10g 0.222 36.4 211.1 
0.15g 0.332 39.9 240.6 
Low 
viscosity 
Syrup 22.00g 
Distilled water 29.00g
0.05g 0.098 30.0 98.1 
0.10g 0.196 31.7 100.5 
0.15g 0.293 31.8 91.9 
 
 
5.3.3 Repeatability Test 
After the effect of syrup concentration and dye concentration on the SVFs 
were investigated, the repeatability test for the present method in producing SVFs 
was performed. Two separate samples for high, medium, and low SVFs were 
prepared according to the same formula listed in Table 5-1, and their viscosities were 
measured. This procedure was repeated six times, and the results are shown in Figs. 
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5-5 and 5-8. As listed in Tables 5-4 to 5-6, the results showed less than 5 % of the 
coefficient of variations over all shear rates, a finding which could effectively 
validate the repeatability of the present method.  
 
 
 
Figure 5-5. Diastolic/systolic viscosity curves obtained from the high level SVF for 
the validation of repeatability 
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Figure 5-6. Diastolic/systolic viscosity curves obtained from the medium level SVF 
for the validation of repeatability 
 
 
Figure 5-7. Diastolic/systolic viscosity curves obtained from the low level SVF for 
the validation of repeatability 
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Table 5-4. The obtained results from high level of SVF for the validation of 
repeatability (1 cP = 10 mP) 
Repeated 
Number 
Shear rate (1/s) 
1,000 300 150 100 50 10 5 2 1 
Viscosity 
(mP) 
Viscosity 
(mP) 
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP) 
Viscosity 
(mP) 
1 
1-1 77.5 79.6 81.6 83.1 87.1 152.3 213.1 363.9 581.9 
1-2 69.8 70.5 71.2 71.7 73.4 134.6 192.6 338.2 551.2 
2 
21 65.3 66.3 67.2 67.9 69.9 131.0 189.4 336.9 553.7 
2-2 66.7 68.1 69.5 70.5 73.3 135.3 194.2 342.5 559.7 
3 
3-1 73.5 74.7 75.8 76.6 78.9 140.2 197.7 340.7 548.3 
3-2 71.8 73.0 74.1 74.9 77.3 139.9 198.8 346.4 561.5 
4 
4-1 72.1 73.4 74.5 75.4 77.9 143.2 205.0 360.3 587.5 
4-2 71.9 72.7 73.4 74.0 75.7 137.1 194.9 339.7 550.7 
5 
5-1 72.4 73.5 74.5 75.2 77.4 142.5 204.3 359.5 586.6 
5-2 67.0 67.9 68.7 69.3 71.2 132.3 190.3 336.6 551.2 
6 
6-1 75.7 76.8 77.8 78.5 80.8 142.0 199.1 340.9 546.1 
6-2 68.6 69.6 70.5 71.2 73.2 137.8 199.6 355.8 585.6 
Mean 71.0 72.2 73.2 74.0 76.3 139.0 198.3 346.8 563.7 
±S.D. ±3.7 ±3.9 ±4.1 ±4.3 ±4.7 ±5.8 ±6.8 ±10.2 ±16.7 
C.V. 0.052 0.054 0.056 0.057 0.062 0.041 0.034 0.029 0.030 
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Table 5-5. The obtained results from medium level of SVF for the validation of 
repeatability (1 cP = 10 mP) 
Repeated 
Number 
Shear rate (1/s) 
1,000 300 150 100 50 10 5 2 1 
Viscosity 
(mP) 
Viscosity 
(mP) 
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP) 
Viscosity 
(mP) 
1 
1-1 36.3 37.9 40.2 42.4 47.7 73.7 96.8 151.9 228.9 
1-2 39.4 39.7 41.3 43.5 48.7 73.7 95.8 148.2 221.0 
2 
21 37.5 38.7 40.8 43.1 48.5 74.6 97.8 153.1 230.3 
2-2 36.8 38.0 40.1 42.4 47.7 73.9 97.3 153.2 231.3 
3 
3-1 37.8 38.7 40.5 42.6 47.7 72.1 93.7 144.9 215.9 
3-2 36.9 37.6 39.4 41.5 46.6 71.2 93.1 145.0 217.4 
4 
4-1 41.7 42.1 44.0 46.4 52.0 79.2 103.3 160.7 240.5 
4-2 37.6 38.4 40.1 42.3 47.3 71.6 93.1 144.2 215.0 
5 
5-1 38.0 38.5 40.2 42.3 47.3 71.4 92.7 143.2 213.2 
5-2 38.2 39.4 41.5 43.8 49.2 75.4 98.7 154.2 231.6 
6 
6-1 37.7 38.6 40.4 42.7 47.8 73.0 95.4 148.6 222.6 
6-2 38.7 39.7 41.6 43.8 48.9 73.8 95.7 147.7 219.8 
Mean 38.1  38.9  40.8 43.1 48.3 73.6 96.1 149.6 224.0 
±S.D. ±1.4  ±1.2  ±1.2 ±1.3 ±1.4 ±2.2 ±3.0 ±5.2  ±8.4  
C.V. 0.037  0.031 0.029 0.029 0.029 0.030 0.031 0.035 0.038 
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Table 5-6. The obtained results from low level of SVF for the validation of 
repeatability (1 cP = 10 mP) 
Repeated 
Number 
Shear rate (1/s) 
1,000 300 150 100 50 10 5 2 1 
Viscosity 
(mP) 
Viscosity 
(mP) 
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP)
Viscosity 
(mP) 
Viscosity 
(mP) 
1 
1-1 27.0 28.0 28.9 29.8 31.8 40.8 48.2 64.9 86.7 
1-2 28.2 29.1 30.0 30.8 32.8 41.5 48.8 64.9 85.8 
2 
21 27.9 29.2 30.3 31.2 33.2 42.4 50.1 67.2 89.5 
2-2 27.2 28.8 30.2 31.1 33.1 42.4 50.1 67.3 89.7 
3 
3-1 28.7 30.1 31.3 32.2 34.3 43.7 51.5 68.8 91.3 
3-2 29.8 31.1 32.2 33.1 35.1 44.2 51.6 68.2 89.6 
4 
4-1 30.0 31.1 32.1 32.9 34.8 43.2 50.1 65.4 85.1 
4-2 28.8 29.7 30.7 31.5 33.4 41.9 49.0 64.7 84.9 
5 
5-1 31.1 31.9 32.8 33.6 35.6 44.5 51.8 68.0 88.9 
5-2 29.0 29.7 30.3 31.1 33.0 41.6 48.6 64.3 84.5 
6 
6-1 27.1 27.8 28.5 29.2 31.0 39.2 46.0 61.0 80.5 
6-2 29.8 30.3 31.0 31.8 33.7 42.5 49.8 65.8 86.6 
Mean 28.7  29.7  30.7 31.5 33.5 42.3 49.6 65.9  86.9  
±S.D. ±1.3  ±1.2  ±1.3 ±1.3 ±1.3 ±1.5 ±1.7 ±2.2  ±3.0  
C.V. 0.045  0.042 0.042 0.041 0.040 0.035 0.033 0.033 0.035 
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5.3.4 Degradation Test with/without EDTA 
In order to investigate the degradation of the prepared SVF samples, mostly 
by deterioration, the SVF samples for high, medium, and low levels of viscosity were 
prepared according to the formula listed in Table 5-1. In addition, the effect of EDTA 
on the change of viscosities of the SVFs was investigated by comparing the measured 
viscosities stored in two different vacutainers, a plain vacutainer (with red cap) and 
an EDTA vacutainer (with purple cap) as shown in Figs. 5-8 and 5-9, respectively. 
 
 
 
Figure 5-8. SVFs in plain vacutainer (right) and EDTA vacutainer (left) 
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Figure 5-9. Samples of SVFs for degradation test used in the present study 
 
 
The SVF samples were stored at 4oC and the degradation of the SVF 
samples was monitored by periodically measuring the viscosities of randomly-
selected samples with intervals of 7 days. 
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Figure 5-10. Viscosity changes of high level of SVF due to degradation for about 6 
months (plain vacutainer) 
 
 
Figure 5-11. Viscosity changes of medium level of SVF due to degradation for about 
6 months (plain vacutainer) 
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Figure 5-12. Viscosity changes of low level of SVF due to degradation for about 6 
months (plain vacutainer) 
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Table 5-7. Viscosity changes of SVFs due to degradation for about 6 months (plain 
vacutainer) (1 cP = 10 mP) 
Plain vacutainer 
 
High viscosity (mP) Medium viscosity (mP) Low viscosity (mP) 
SBV DBV SBV DBV SBV DBV 
DAY 0 71.5  546.1 39.2  239.5  31.2  87.3  
DAY 7 
74.9  527.2 36.0  209.7  31.5  87.9  
74.0  557.8 40.2  218.0  29.3  86.2  
DAY 14 
68.5  494.7 36.9  194.9  31.2  87.3  
70.4  515.8 36.0  203.4  30.3  82.3  
DAY 21 
69.1  559.9 40.3  217.6  27.9  83.6  
64.7  501.0 39.5  230.3  30.2  81.7  
DAY 28 
67.7  538.4 37.8  204.8  29.0  81.8  
69.6  537.5 36.6  216.2  29.2  87.9  
DAY 35 
60.1  524.1 37.9  230.2  29.6  81.6  
69.4  532.3 36.8  219.2  29.5  82.7  
DAY 42 
68.2  571.1 36.5  218.2  28.2  82.4  
68.3  533.4 38.5  227.9  29.3  89.0  
DAY 49 
67.2  521.6 37.8  223.6  30.4  86.5  
66.2  536.7 36.7  205.7  29.3  87.5  
DAY 56 
62.8  484.5 38.5  225.3  32.6  89.0  
73.1  581.1 39.8  230.3  29.0  81.0  
… … … … … … … 
DAY 190 
71.6  545.5 69.0  241.1  32.3  90.1  
75.0  599.8 40.5  253.1  31.7  97.0  
DAY 191 
66.6  548.3 41.4  245.0  30.1  87.1  
80.3  559.7 41.6  290.5  28.9  82.7  
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Figure 5-13. Viscosity changes of high level of SVF due to degradation for about 6 
months (EDTA vacutainer) 
 
\  
Figure 5-14. Viscosity changes of medium level of SVF due to degradation for about 
6 months (EDTA vacutainer) 
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Figure 5-15. Viscosity changes of low level of SVF due to degradation for about 6 
months (EDTA vacutainer) 
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Table 5-8. Viscosity changes of the SVFs due to degradation for about 6 months 
(EDTA vacutainer) (1 cP = 10 mP) 
EDTA Vacutainer 
 
High viscosity (mP) Medium viscosity (mP) Low viscosity (mP) 
SBV DBV SBV DBV SBV DBV 
DAY 0 79.8  586.4 39.5  243.7 28.8  85.6  
DAY 7 
70.8  564.8 40.1  236.4 30.9  86.1  
73.3  536.9 41.3  231.4 30.9  84.3  
DAY 14 
76.7  489.6 42.9  241.6 27.6  78.6  
74.9  526.2 40.2  223.8 28.4  76.7  
DAY 21 
73.0  509.3 38.7  211.4 30.8  95.8  
69.9  499.5 37.3  219.4 31.5  95.6  
DAY 28 
69.1  536.0 40.0  208.3 30.2  86.4  
70.2  516.0 38.5  220.2 29.4  85.4  
DAY 35 
68.6  506.1 36.5  212.0 28.2  84.1  
69.5  524.8 38.4  214.4 29.6  91.6  
DAY 42 
68.2  577.0 37.0  214.9 29.7  84.8  
73.4  531.8 39.2  237.6 31.4  94.1  
DAY 49 
73.5  535.4 39.6  212.0 30.8  86.5  
69.6  534.7 37.5  204.8 29.7  83.0  
DAY 56 
66.2  533.3 39.6  213.3 28.5  85.0  
73.2  527.2 38.1  222.1 31.0  87.7  
… … … … … … … 
DAY 190 
73.4  608.4 39.4  248.4 27.1  85.5  
78.0  578.5 42.5  260.5 31.1  99.0  
DAY 191 
75.9  600.3 40.6 260.8 31.2  98.8  
79.3  585.0 39.7 208.9 32.0  119.3  
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Figures 5-6 to 5-12 and Table 5-7 showed the results of viscosity change of 
the SVFs in a plain vacutainer due to degradation measured at intervals of 7 days. 
Based on the Figs. 5-6 and 5-12, the viscosity of the SVFs in a plain vacutainer began 
to show a significant change after about 56 days. The coefficient of variation over the 
period was less than 5% within 56 days, and after 56 days, the variation gradually 
increased over 5% over time. 
The lower the viscosity among the high, medium, and low SVFs, the larger difference 
due to degradation was observed, indicating that even though the same amount of 
degradation had been occurred by deterioration, the low SVF might have been 
affected more significantly due to its low concentration of syrup. 
The viscosity of SVFs between plain and EDTA vacutainers showed no 
significant difference when compared with Figs. 5-13 and 5-15 and Table 5-8. 
 
5.4 Limitations 
The present study showed the applicability of new opaque SVFs by dye 
concentration, repeatability, and degradation tests for blood viscosity measurement 
using the SCTV. 
In degradation tests of the SVFs, it was verified that the sample showed stable 
viscosity over about 2 months, and after that, its non-Newtonian viscosity property 
was gradually altered by deterioration. Here, the mechanism of degradation was not 
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exactly known. Further investigation might be required in order to improve its quality 
and accuracy of the opaque SVFs over an extended period by preventing the 
degradation process. 
By adopting low molecular-weight materials as used in the present study with 
various kinds of chain structures, the non-Newtonian viscosity behavior of blood 
caused by the aggregation of RBCs with intermolecular forces was able to be 
replicated. It would be also interesting to investigate the mechanism on how to 
replicate the effects of the deformability of RBCs within the SVF, a task which has 
not been investigated in the present study. 
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CHAPTER 6: CONCLUSIONS 
Blood viscosity, which represents the frictional resistance between a moving 
blood and stationary vessel walls, was suggested as the hidden link between 
cardiovascular disease and the related risk factors from a biomechanical approach 
[159]. The present study covered the followings: 1) a new hematocrit-correction 
method of measured WBV profiles, 2) a new in-line method to measure 
hemorheological property (i.e. hematocrit), 3) the application of DBD and corona 
discharges to improve blood viscosity, and 4) a new SVF for blood viscosity 
measurement using the SCTV. 
6.1 A New Hematocrit-Correction Model  
A new hematocrit-correction model to correct the measured WBV at native 
hematocrit to a standard hematocrit of 45 % was successfully completed, resulting in 
less errors and deviations over a wide range of shear rates than the Matrai’s model 
[45]. The new model does not require the measurement of plasma viscosity. The new 
model showed the maximum negative and positive deviations by -6.7% to 8.5 % from 
the measured WBV at 45 % hematocrit, which were about 4 to 6 times less than those 
from the Matrai’s model. The applicability of the new model was also visually 
demonstrated by plotting the corrected WBV profiles to the measured WBV profile at 
45 % hematocrit with no significant difference. Thus, it is concluded that once the 
yield stress and the Casson constant are obtained by either the SCTV or any other 
means, the corrected WBV can be accurately calculated over a wide range of shear 
rates using the new model without the need of the plasma viscosity. 
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6.2 A New On-Line Conductance Cell for Hematocrit Measurements 
A new method of measuring the electric conductivity of whole blood for the 
purpose of hematocrit measurement was successfully validated through experimental 
tests. The new measurement method of the conductivity of blood produced stable and 
noise free data, without the usual error associated with the conventional method due 
to the sedimentation of erythrocytes. The conductivity of whole blood measured from 
the conductance cell was compared with hematocrits obtained from microcentrifuge 
over a wide range of hematocrits, 20-65 %. The present study demonstrated that a 
simple but accurate hematocrit measurement could be achieved by employing a low-
frequency square-wave voltage signal in a conductance cell. The present conductivity 
measurement method could open a door for a possible integration of the present on-
line hematocrit measurement to other blood property measuring devices such as a 
blood viscometer.  
 
6.3 Plasma Discharge Treatment to Improve Hemorheological Properties 
A new physical treatment method with the application of high voltage 
electrical plasma discharges (i.e. DBD and corona discharge) followed by filtration of 
the coagulated particles was validated through experimental tests in the present study. 
The results indicated that the plasma discharge treatment could precipitate and 
coagulate plasma proteins (i.e., fibrinogen) and LDL molecules in blood plasma. The 
177 
 
DBD treatment produced the formation of white layer on the surface of blood plasma, 
confirming the precipitation and coagulation of plasma proteins and lipids in blood 
plasma. WBV could be significantly reduced by 9.1 and 17.7 % for SBV and DBV, 
respectively, from the respective baseline values when DBD-treated blood plasma 
was filtered prior to mixing with red blood cells. When treated with the corona 
discharge, DBV dropped by about 30.1 % from the baseline value, whereas the SBV 
showed no significant change. However, the measurements of LDL molecules in the 
corona-treated blood plasma for 60 pulses showed a drop in the LDL concentration 
by 31.5 %, from 132.8 to 90.0 mg/dL after filtration. 
 
6.4 A Standard Viscosity Fluid for Blood Viscosity Measurements 
A new opaque SVF was proposed using maltose with 55 % of concentration 
to replicate the non-Newtonian shear-thinning behavior of blood viscosity for 
different shear rates. The produced viscosity profiles from three different levels of 
SVFs gave a good agreement with WBV profiles over a wide range of shear rates. In 
particular, the medium level SVF gave an excellent agreement with normal blood 
viscosity profile. The applicability of new opaque SVFs was demonstrated by 
repeatability test with coefficient of variations less than 5 % , dye concentration test, 
achieving the minimum detectable concentration of dye as low as about 0.2 % by 
weight, degradation test with coefficient of variations less than 5 % over 
approximately 2 months, and anti-coagulant test with no significant difference 
between plain and EDTA vacutainers.  
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In summary, the ultimate goal of a blood viscosity study is to utilize WBV as 
a means to promote health and save lives as the WBV can be used as a biomarker or a 
risk factor for the prediction, diagnosis, treatment, and prevention of various 
circulatory diseases. 
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